0001493152-20-015226.txt : 20200811 0001493152-20-015226.hdr.sgml : 20200811 20200811152017 ACCESSION NUMBER: 0001493152-20-015226 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200811 DATE AS OF CHANGE: 20200811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eWELLNESS HEALTHCARE Corp CENTRAL INDEX KEY: 0001550020 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 451560906 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55203 FILM NUMBER: 201092214 BUSINESS ADDRESS: STREET 1: 333 LAS OLAS WAY, SUITE 100 CITY: FT LAUDERDALE STATE: FL ZIP: 33301 BUSINESS PHONE: 855-470-1700 MAIL ADDRESS: STREET 1: 333 LAS OLAS WAY, SUITE 100 CITY: FT LAUDERDALE STATE: FL ZIP: 33301 FORMER COMPANY: FORMER CONFORMED NAME: Dignyte, Inc. DATE OF NAME CHANGE: 20120515 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2020

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 000-55203

 

 

eWELLNESS HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada   90-1073143
(State or other jurisdiction
of incorporation or organization)		  

(I.R.S. Employer

Identification No.)

 

1126 S Federal Hwy #464, Fort Lauderdale, FL   33316
(Address of principal executive offices)   (Zip Code)

 

(855) 470-1700

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common shares   EWLL   OTC

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Ruble 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ]
   
Non-accelerated filer [  ] (Do not check if a smaller reporting company) Smaller reporting company [X]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ] No [X]

 

The number of shares of Common Stock, $0.001 per share par value, outstanding on August 7, 2020 was 8,732,404,469.

 

 

 

 

 

 

Table of Contents

 

  Page
PART I - FINANCIAL INFORMATION 3
Item 1 Financial Statements 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
Item 3 Quantitative and Qualitative Disclosures About Market Risk 18
Item 4 Controls and Procedures 18
PART II - OTHER INFORMATION 19
Item 1 Unregistered Sales of Equity Securities and Use of Proceeds 19
Item 2 Exhibits 20
Signatures 21

 

2

 

 

PART I – FINANCIAL STATEMENTS

 

ITEM 1. FINANCIAL STATEMENTS

 

eWELLNESS HEALTHCARE CORPORATION

CONSOLIDATED CONDENSED BALANCE SHEETS

(unaudited)

 

   June 30, 2020   December 31, 2019 
         
ASSETS          
           
CURRENT ASSETS          
Cash  $4,075   $240,722 
Accounts Receivable   129,872    3,635 
Prepaid expenses   21,763    157,139 
           
Total current assets   155,710    401,496 
           
Property & equipment, net   16,268    22,810 
Intangible assets, net   8,000    9,000 
           
TOTAL ASSETS  $179,978   $433,306 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES          
Accounts payable and accrued expenses  $733,025   $314,287 
Accounts payable - related party   782,832    582,832 
Accrued expenses - related party   121,107    138,868 
Accrued compensation   357,965    532,974 
Convertible debt, net of discount   1,977,769    2,240,408 
Derivative liability   4,297,437    3,529,974 
           
Total current liabilities   8,270,135    7,339,343 
           
Total Liabilities   8,270,135    7,339,343 
           
COMMITMENTS AND CONTINGENCIES   -    - 
           
STOCKHOLDERS’ DEFICIT          
Preferred stock, authorized 20,000,000 shares, $.001 par value, 476,667 and 250,000 shares issued and outstanding, respectively   477    250 
Common stock, authorized 20,000,000,000 shares, $.001 par value, 7,851,724,496 and 12,752,084 issued and outstanding, respectively   7,851,725    12,752 
Shares to be issued   76    150 
Additional paid in capital   21,409,110    23,942,830 
Accumulated deficit   (37,351,545)   (30,862,019)
           
Total Stockholders’ Deficit   (8,090,157)   (6,906,037)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $179,978   $433,306 

 

The accompanying notes are an integral part of these consolidated condensed financial statements

 

3

 

 

eWELLNESS HEALTHCARE CORPORATION

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

For the Three and Six Months ended June 30, 2020 and 2019

(unaudited)

 

   Three Months Ended   Six Months Ended 
   June 30, 2020   June 30, 2019   June 30, 2020   June 30, 2019 
                 
REVENUE  $123,780   $-   $138,155   $- 
                     
OPERATING EXPENSES                    
Executive compensation   187,000    102,000    374,000    204,000 
General and administrative   88,553    324,858    435,243    575,352 
Professional fees   383,163    534,980    850,581    1,249,141 
                     
Total Operating Expenses   658,716    961,838    1,659,824    2,028,493 
                     
Loss from Operations   (534,936)   (961,838)   (1,521,669)   (2,028,493)
                     
OTHER INCOME (EXPENSE)                    
Interest income   -    6    1    17 
Gain (loss) on derivative liability   (2,217,052)   (61,431)   (4,199,959)   617,967 
Loss on disposal of asset   (3,866)   -    (3,866)   - 
Interest expense   (205,073)   (742,047)   (764,033)   (1,693,272)
                     
Net Loss before Income Taxes   (2,960,927)   (1,765,310)   (6,489,526)   (3,103,781)
                     
Income tax expense   -    -    -    - 
                     
Net Loss  $(2,960,927)  $(1,765,310)  $(6,489,526)  $(3,103,781)
                     
Basic and diluted (loss) per share  $(0.00)  $(0.01)  $(0.00)  $(0.01)
                     
Weighted average shares outstanding   5,181,476,648    219,592,981    2,672,747,473    215,560,585 

 

The accompanying notes are an integral part of these consolidated condensed financial statements

 

4

 

 

eWELLNESS HEALTHCARE CORPORATION

RECONCILIATION OF STOCKHOLDERS’ DEFICIT

(unaudited)

 

THREE MONTHS ENDED JUNE 30, 2020 AND 2019

 

               Additional       Total 
   Preferred Shares   Common Shares   Shares to   Paid in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   be Issued   Capital   Deficit   Deficit 
                                 
Balance at March 31, 2020   375,000   $375    1,430,005,454   $1,430,006   $-   $26,285,825   $(34,390,618)  $(6,674,412)
                                         
Contributed services   -    -    -    -    -    54,000    -    54,000 
                                         
Shares issued to officers, directors and consultants   101,667    102    -    -    -    304,898    -    305,000 
                                         
Shares issued for debt conversion   -    -    6,421,465,710    6,421,466    -    (6,047,649)   -    373,817 
                                         
Shares issued for services   -    -    253,332    253    76    (201)   -    128 
                                         
Derivative liability   -    -    -    -    -    812,237    -    812,237 
                                         
Net loss   -    -    -    -    -    -    (2,960,927)   (2,960,927)
                                         
Balance at June 30, 2020   476,667   $477    7,851,724,496   $7,851,725   $76   $21,409,110   $(37,351,545)  $(8,090,157)
                                         
Balance at March 31, 2019   -   $-    4,346,792   $4,346   $-   $19,012,024   $(22,739,705)  $(3,723,334)
                                         
Contributed services   -    -    -    -    -    54,000    -    54,000 
                                         
Shares issued for debt conversion   -    -    23,629    24    -    53,732    -    53,756 
                                         
Shares issued for cash   -    -    16,000    16    -    59,084    -    59,100 
                                         
Shares issued for prepaid services   -    -    10,000    10    -    52,990    -    53,000 
                                         
Shares issued for services   -    -    33,009    33    -    158,051    -    158,084 
                                         
Derivative liability   -    -    -    -    -    70,987    -    70,987 
                                         
Net loss   -    -    -    -    -    -    (1,765,310)   (1,765,310)
                                         
Balance at June 30, 2019   -   $-    4,429,430   $4,429   $-   $19,460,868   $(24,505,015)  $(5,039,718)

 

SIX MONTHS ENDED JUNE 30, 2020 AND 2019

 

   Preferred Shares   Common Shares   Shares to   Additional
Paid in		   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   be Issued   Capital   Deficit   Deficit 
                                 
Balance at January 1, 2020   250,000   $250    12,752,084   $12,752   $150   $23,942,830   $(30,862,019)  $(6,906,037)
                                         
Contributed services   -    -    -    -    -    108,000    -    108,000 
                                         
Shares issued to officers, directors and consultants   226,667    227    -    -    -    679,773    -    680,000 
                                         
Shares issued for debt conversion   -    -    7,838,256,204    7,838,257    -    (6,681,896)   -    1,156,361 
                                         
Shares issued for services   -    -    668,332    668    (74)   191    -    785 
                                         
Shares issued for rounding – 50:1 split   -    -    47,876    48    -    (48)   -    - 
                                         
Derivative liability   -    -    -    -    -    3,360,260    -    3,360,260 
                                         
Net loss   -    -    -    -    -    -    (6,489,526)   (6,489,526)
                                         
Balance at June 30, 2020   476,667   $477    7,851,724,496   $7,851,725   $76   $21,409,110   $(37,351,545)  $(8,090,157)
                                         
Balance at January 1, 2019   -   $-    4,128,139   $4,128   $-   $17,416,117   $(21,401,234)  $(3,980,989)
                                         
Contributed services   -    -    -    -    -    108,000    -    108,000 
                                         
Shares issued for debt conversion   -    -    125,574    125    -    401,117    -    401,242 
                                         
Shares issued for cash   -    -    16,000    16    -    59,084    -    59,100 
                                         
Shares issued for financing costs   —    -    20,000    20         114,980         115,000 
                                         
Shares issued for prepaid services   -    -    80,217    80    -    458,670         458,750 
                                         
Shares issued for services   -    -    59,500    60    -    339,573    -    339,633 
                                         
Derivative liability   -    -    -    -    -    563,327    -    563,327 
                                         
Net loss   -    -    -    -    -    -    (3,103,781)   (3,103,781)
                                         
Balance at June 30, 2019   -   $-    4,429,430   $4,429   $-   $19,460,868   $(24,505,015)  $(5,039,718)

 

The accompanying notes are an integral part of these consolidated condensed financial statements

 

5

 

 

eWELLNESS HEALTHCARE CORPORATION

CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS

(unaudited)

 

   For the Six Months Ended 
   June 30, 2020   June 30, 2019 
         
Cash flows from operating activities          
Net loss  $(6,489,526)  $(3,103,781)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   3,676    2,840 
Contributed services   108,000    108,000 
Shares issued for officers, directors and consultants   344,960    - 
Shares issued for consulting services   785    339,633 
Shares issued for financing costs   93,433    115,000 
Amortization of debt discount and prepaids   725,250    1,736,987 
(Gain) loss on derivative liability   4,199,959    (617,967)
Loss on disposal of asset   3,866    - 
Changes in operating assets and liabilities          
Prepaid expense   (9,916)   (37,628)
Accounts receivable   (126,237)   - 
Accounts payable and accrued expenses   513,643    83,297 
Accounts payable - related party   196,460    (9,981)
Accrued expenses - related party   31,509    (13,560)
Accrued compensation   122,491    (43,279)
           
Net cash used in operating activities   (281,647)   (1,440,439)
           
Cash flows from investing activities          
Purchase of equipment   -    (541)
Net cash used in investing activities   -    (541)
           
Cash flows from financing activities          
Proceeds from issuance of common stock   -    59,100 
Issuance of convertible debt   52,800    1,968,900 
Payments on debt   -    (639,550)
Debt issuance costs   (7,800)   (248,150)
           
Net cash provided by financing activities   45,000    1,140,300 
           
Net increase (decrease) in cash   (236,647)   (300,680)
           
Cash, beginning of period   240,722    383,335 
           
Cash, end of period  $4,075   $82,655 
           
Supplemental Information:          
Cash paid for:          
Taxes  $-   $1,856 
Interest Expense  $-   $275,814 
Non cash items:          
Derivative liability and debt discount issued with new notes  $-   $1,769,048 
Shares issued for debt conversion  $1,156,360   $401,242 
Shares issued for prepaids  $-   $458,750 

 

The accompanying notes are an integral part of these consolidated condensed financial statements

 

6

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

June 30, 2020

(unaudited)

 

Note 1. The Company

 

The Company and Nature of Business

 

eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated minimal revenues to date.

 

eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. Our business model is to have large-scale employers use our PHZIO platform as a fully PT monitored corporate musculoskeletal treatment (“MSK”) wellness program. The Company’s PHZIO home physical therapy assessment and exercise platform has been designed to disrupt the $30 billion physical therapy market, the $4 billion MSK market and the $8 billion corporate wellness industry. PHZIO re-defines the way MSK physical therapy can be delivered. PHZIO is the first real-time remote monitored 1-to-many MSK physical therapy platforms for home use.

 

On May 22, 2020, the Company received and accepted the resignations of Brandon Rowberry and Rochelle Pleskow as independent directors. Their letters of resignation state the reason for their resignations were to permit them to pursue other business opportunities and further stated that they have had no disagreements with the operations, policies or practices of the Company. Also, on May 22, 2020, the Company received a letter of resignation from Darwin Fogt resigning as CEO, President and director of the Company and a separate letter of resignation from Curtis Hollister, resigning as CTO and director of the Company. Messrs. Fogt and Hollister are executive officers and principals of Bistromatics Inc., organized under the laws of Canada (“Bistromatics”).

 

On November 12, 2016, the Company entered into a Services Agreement with Bistromatics (the “Bistromatics Agreement”) pursuant to which Bistromatics agreed to provide operational services to the Company for its PHZIO System including development, content editing and training, support and maintenance, billing, hosting and oversight, among other services. Reference is made to the Company’s Form 8-K filed on November 21, 2016, which Form 8-K was signed by Darwin Fogt as CEO on behalf of the Company, regarding the disclosure of the Bistromatics Agreement. The Services Agreement included a provision granting Bistromatics the right to appoint 40% of the Registrant’s Board of Directors, resulting in the appointment of Messrs. Fogt and Hollister as members of the Company’s Board. Although both Companies continue to abide by the Services Agreement the Company is in arrears in fees to Bistromatics for approximately $750,000 as of March 31, 2020. The Service Agreement expired during the 1st quarter of 2020 and the parties continue to discuss the formation of a new Services Agreement.

 

Pursuant to communications between the Company and Darwin Fogt and Curtis Hollister regarding their resignations as executive officers and directors of the Company, which resignations were accepted by the Company’s Board on June 1, 2020, Messrs. Fogt and Hollister represented to the Company that Bistromatics and its management will continue to provide support services to the Company’s PHZIO System, In addition, both Darwin Fogt and Curtis Hollister confirmed that they have had no disagreements with the operations, policies or practices of the Company.

 

In connection with the resignation of Darwin Fogt as CEO, the Registrant’s Board of Directors has appointed Douglas MacLellan, who has served as the Company’s Chairman since May 2013, as Chief Executive Officer in addition to continuing to serve as the Chairman of the Board of Directors.

 

As noted above, the Companies PHZIO and MSK360 systems are currently operated on behalf of the Company by Bistromatics Inc. in Canada. These services are still operational and continues to treat EWLL’s corporate patients and customers.

 

We are in the process of completing a new Services Agreement with Bistromatics, that, when completed, will likely re-position EWLL as a Value Added Reseller (“VAR”) of the PHZIO & MSK360 platforms and allow EWLL to earn marketing fees and would also be granted a significant percentage ownership of Bistromatics in return for  transferring the marketing and IP rights for the PHZIO and MSK360 platforms from EWLL to Bistromatics.

 

7

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

June 30, 2020

(unaudited)

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2020 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2020. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019.

 

The information regarding common stock shares, options and warrants throughout this document have been adjusted to reflect the 1:50 reverse split authorized by the Board of Directors on December 16, 2019 and further approved by FINRA on February 12, 2020.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 

Going Concern

 

For the six months ended June 30, 2020, the Company had revenues of $138,155. The Company has an accumulated loss of $37,351,545 and a working capital deficit of $8,114,425. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Fair Value of Financial Instruments

 

As of June 30, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $4,297,437   $           -   $            -   $4,297,437 
Total Liabilities measured at fair value  $4,297,437   $-   $-   $4,297,437 

 

8

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

June 30, 2020

(unaudited)

 

As of December 31, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,529,974   $           -   $            -   $3,529,974 
Total Liabilities measured at fair value  $3,529,974   $-   $-   $3,529,974 

 

Note 3. Related Party Transactions

 

In November 2016, the Company signed an agreement with a programming company (“PC”) within which one of the Company’s former directors and Chief Technical Officer (“CTO”) is the Chief Marketing Officer. The agreement is for additional features to be programmed for the launch of the PHZIO platform. The Company is to pay a monthly base fee of $100,000 for the development and compensation for the Company’s CEO and CTO. Following payment of the initial $100,000, the Company is obligated to only pay $50,000 monthly until the PC has successfully signed and collected the first monthly service fee for 100 physical therapy clinics to use the PHZIO platform. The PC will also have the right to appoint 40% of the directors. At the periods ended June 30, 2020 and December 31, 2019, the Company had a payable of $782,832 and $582,832, respectively. The CTO resigned his officer and director position on June 1, 2020.

 

The Company signed an agreement with the former CEO for administrative physical therapy consulting. The agreement provides that the former CEO will provide non-clinical administrative services in the various states where the Phzio companies are located. The Company is to pay the former CEO the sum of $3,500 per month. Since the former CEO resigned his officer and director position on June 1, 2020, any amounts owed to him are included in accounts payable.

 

Throughout the six months ended June 30, 2020, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of June 30, 2020 and December 31, 2019 were $0 and $1,368, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $121,107 and $137,500 as of June 30, 2020 and December 31, 2019, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $357,965 and $532,974 as of June 30, 2020 and December 31, 2019, respectively.

 

Note 4. Convertible Notes Payable

 

Six Months Ended June 30, 2020

 

In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. During the six months ended June 30, 2020, the Company accrued interest expense of $1,719.

 

9

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

June 30, 2020

(unaudited)

 

Note 5. Equity Transactions

 

Preferred Stock

 

The total number of shares of preferred stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $0.001 per share. During the year ended December 31, 2019, the Company authorized the issuance of 1,000,000 shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $3,000,000 and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two directors resigned and on June 1, 2020, three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. During the six months ended June 30, 2020, there were 226,667 preferred shares that vested and $297,500 was recorded to reduce accrued compensation; $37,250 was recorded to reduce accrued directors’ fees, and $345,250 was recorded as expense for a total of $680,000. As of June 30, 2020, there were 476,667 vested preferred shares for a total value of $1,430,000.

 

In April 2020, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series D Preferred Stock in which the Board authorized a new series of Preferred Stock to be designated as Series D. The Board authorized two hundred thousand (200,000) shares to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock.

 

The Series D Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation other than the Corporation’s newly authorized 13% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred”); (ii) on parity with all equity securities issued by the Corporation with terms specifically providing that the Series B Preferred ranks on parity, except with respect to voting rights on which the Series B Preferred ranks junior to the Series D Preferred and except with respect to rights to the payment of dividends and the distribution of assets upon any liquidation, dissolution or winding up of the Corporation, which the Series B Preferred ranks senior to the Series D Preferred; and (iii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others in) existing subsidiaries of the Corporation. The term “equity securities” shall not include convertible debt securities The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time.

 

10

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

June 30, 2020

(unaudited)

 

Common Stock

 

On February 12, 2020, FINRA approved a 1:50 reverse split of the Company’s common stock. As noted throughout this document, all common shares are stated as if the 1:50 reverse split had been completed as of the beginning of the year ended December 31, 2019. Following the approval, the Company’s stock began trading under the symbol “EWLLD”. Due to rounding issues for the reverse split, the Company issued 47,876 additional shares of common stock.

 

On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (1,900,000,000) shares of Common Stock to twenty billion (20,000,000,000) shares of Common Stock. On February 19, 2019, the Company filed Articles of Amendment to the Company’s Articles of Incorporation to implement the Authorized Common Stock Share Increase with the State of Nevada.

 

Six Months Ended June 30, 2020

 

In January 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 shares of common stock monthly. The Company issued 80,000 shares of common stock with a value of $126. The Company needs to issue an additional 40,000 shares of common stock with a value of $8. In addition, the Company is to also pay the advisor a monthly fee of $2,500.

 

During the six months ended June 30, 2020, the Company issued a total of 7,838,256,204 shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $959,835 of principal, $103,093 of accrued interest and $93,433 of financing costs.

 

During the six months ended June 30, 2020, the Company issued 588,332 shares of common stock for consultant services valued at $1,597.

 

Six Months Ended June 30, 2019

 

On February 7, 2019, the Company executed an amendment to a contract executed on April 8, 2018 for twelve months for consulting services. The Company issued 5,000 shares of common stock at the signing of the contract valued at $30,500 that is being amortized over the life of the contract.

 

On March 22, 2019, the Company issued 65,217 shares of common stock to an institutional investor as part of a promissory note. These shares are returnable if the Company repays the promissory note before the maturity date. The value of these shares is $375,000 which was recorded as prepaid until the six-month maturity has passed. The Company also issued 20,000 shares of common stock to the institutional investor as a commitment fee. The value of these shares is $115,000.

 

On April 2, 2019, the Company issued 16,000 shares of common stock pursuant to a capital call notice in relation to an Equity Purchase Agreement dated June 18, 2018. The capital call totaled $59,100.

 

On May 17, 2019, the Company executed a contract for three months for consulting services. The Company issued 10,000 shares of common stock at the signing of the contract valued at $53,000 that is being amortized over the life of the contract. At the end of the three months, the Company is to issue another 10,000 shares of common stock.

 

During the six months ended June 30, 2019, the Company issued 59,500 shares of common stock to consultants for services rendered in accordance to consulting agreements. The value of these shares is $339,633.

 

During the six months ended June 30, 2019, the Company issued 125,574 shares of common stock for debt conversion totaling $401,242 which includes $380,250 principal, $18,992 accrued interest and $2,000 due diligence fee.

 

Stock Options

 

The following is a summary of the status of all Company’s stock options as of June 30, 2020 and changes during the six months ended on that date:

 

11

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

June 30, 2020

(unaudited)

 

       Weighted         
   Number
of Stock		   Average
Exercise		   Remaining   Intrinsic 
   Options   Price   Life (yrs)   Value 
Outstanding at December 31, 2019   57,000   $40.00    1.1   $              - 
Granted   -    -           
Exercised   -    -           
Cancelled   -    -           
Outstanding at June 30, 2020   57,000    40.00    .6   $- 
Options exercisable at June 30, 2020   57,000   $40.00    .6   $- 

 

Warrants

 

The following is a summary of the status of the Company’s warrants as of June 30, 2020 and changes during the six months ended on that date:

 

       Weighted         
   Number of   Average
Exercise		   Remaining   Intrinsic 
   Warrants   Price   Life (yrs.)   Value 
Outstanding at December 31, 2019   42,015   $11.94    1.9   $             - 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (10,000)   17.50    -    - 
Outstanding at June 30, 2020   32,015   $10.20    1.0   $- 
Warrants exercisable at June 30, 2020   32,015   $10.20    1.0   $- 

 

Note 6. Commitments, Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

 

12

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

June 30, 2020

(unaudited)

 

Note 7. Derivative Valuation

 

The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.

 

The debt discount is amortized over the life of the note and recognized as interest expense. For the six months ended June 30, 2020 and 2019, the Company amortized the debt discount of $594,705 and $1,401,501, respectively.

 

During the six months ended June 30, 2020, the Company had the following activity in the derivative liability account:

 

   Notes 
Derivative liability at December 31, 2019  $3,529,974 
Addition of new conversion option derivatives   - 
Conversion of note derivatives   (3,432,496)
Change in fair value   4,199,959 
Derivative liability at June 30, 2020  $4,297,437 

 

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

Stock price at valuation date  $.0002 
Exercise price of warrants  $12.50 
Conversion rate of convertible debt  $.00007-.00014 
Risk free interest rate   .10%-.27%
Stock volatility factor   347.96-1322.92%
Years to Maturity   .02 – .55 
Expected dividend yield   None 

 

Note 8. Subsequent Events

 

From July 1 until the filing of this report, the Company issued 880,679,972 shares of common stock for convertible debt conversion totaling $54,322 which includes $50,362 principal and $3,960 accrued interest

 

13

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report include forward-looking statements. These forward-looking statements are based on our management’s current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “proposed,” “intended,” or “continue” or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other “forward-looking” information. Many factors could cause our actual results to differ materially from those projected in these forward-looking statements, including but not limited to: variability of our future revenues and financial performance; risks associated with product development and technological changes; the acceptance of our products in the marketplace by potential future customers; general economic conditions. You should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.

 

The following discussion and analysis of financial condition and results of operations relates to the operations and financial condition reported in the financial statements of eWellness Healthcare Corporation for the six months ended June 30, 2020 and 2019 and should be read in conjunction with such financial statements and related notes included in this report and the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

 

THE COMPANY

 

Overview

 

eWellness Healthcare Corporation is a provider of the state of the art PHZIO platform for the physical therapy (“PT”) and telehealth markets and believes it is the first digital telehealth physical therapy company (“dtPT Company”) to offer real-time monitored physical therapy assessments and treatments to large-scale employers. The Company’s digital telehealth assessment and treatment platform (the “dtPT Platform” or “Platform”) has been designed to serve the $30 billion physical therapy market, the $4 billion musculoskeletal (“MSK”) market and the $8 billion corporate wellness market. Our dtPT Platform redefines the way physical therapy (“PT”) can be delivered. We believe that our Platform is able to transform the access, cost and quality dynamics of PT assessments and treatments. We began generating revenue during the fourth quarter of 2019.

 

We designed our Platform to enable its usage for all PT assessments and treatments by means of computer, smart phone and/or similar digital media devices (the “Access Devices”). This new approach will lower patient treatment costs, expand patient treatment access and improve patient compliance. Our dtPT Platform allows patients to avoid the time-consuming clinical experience to an immediate in-home PT experience. We believe that approximately 80% of all PT assessments and treatments can be performed using our Platform accessible via the Access Devices in the privacy of once home.

 

We believe that our innovative approach to solving the pervasive access, cost and quality challenges facing the current access to PT clinics, will lead to highly scalable and substantial growth in our revenues. The Company has signed 7 partnership and healthcare provider agreements to date. We believe that we are well positioned to participate in the rapidly evolving PT treatment market by introducing our innovative dtPT Platform enabling remote patient monitoring, post-discharge treatment plan adherence and in-home care. Our Platform incorporates research-based methods and focuses on, not only rehabilitation but also wellness, functional fitness, performance, and prevention.

 

14

 

 

Our PHZIO and MSK 360 platforms completely disrupts the current in-clinic business model of the $30 billion PT industry, the 4 billion MSK market and the $8 billion corporate wellness industries. Innovators in other industries have solved access, cost and quality inefficiencies through the implementation of technology platforms and business models that deliver products and services on-demand and create new economies by connecting and empowering both consumers and businesses. We have taken the same approach to solving the pervasive access, cost and quality challenges facing the current access to PT and MSK clinics. eWellness’ underlying technology platform is complex, deeply integrated and purpose-built over the past five years for the evolving PT and MSK treatment marketplaces. eWellness’ PHZIO and MSK 360 platforms are highly scalable and can support substantial growth of third-party licensees. eWellness’ PHZIO and MSK 360 platforms provides for broad interconnectivity between PT practitioners and their patients, uniquely positioning the Company as a focal point in the rapidly evolving PT industry to introduce innovative, technology- based solutions, such as remote patient monitoring, post-discharge treatment plan adherence and in-home care.

 

On May 22, 2020, the Company received and accepted the resignations of Brandon Rowberry and Rochelle Pleskow as independent directors. Their letters of resignation dated May 22, 2020, state that the reason for their resignations were to permit them to pursue other business opportunities and further stated that they have had no disagreements with the operations, policies or practices of the Company. Also, on May 22, 2020, the Company received a letter of resignation from Darwin Fogt, resigning as CEO, President and director of the Registrant and a separate letter of resignation from Curtis Hollister, resigning as CTO and director of the Company. Messrs. Fogt and Hollister are executive officers and principals of Bistromatics Inc., organized under the laws of Canada (“Bistromatics”).

 

On November 12, 2016, the Company entered into a Services Agreement with Bistromatics (the “Bistromatics Agreement”) pursuant to which Bistromatics agreed to provide operational services to the Company for its PHZIO System including development, content editing and training, support and maintenance, billing, hosting and oversight, among other services. Reference is made to the Registrant’s Form 8-K filed on November 21, 2016, which Form 8-K was signed by Darwin Fogt as CEO on behalf of the Registrant, regarding the disclosure of the Bistromatics Agreement. The Services Agreement included a provision granting Bistromatics the right to appoint 40% of the Registrant’s Board of Directors, resulting in the appointment of Messrs. Fogt and Hollister as members of the Company’s Board. Although both Companies continue to abide by the Services Agreement the Company is in arrears in fees to Bistromatics for approximately $750,000 as of March 31, 2020. The Service Agreement expired during the first quarter of 2020 and the parties continue to discuss the formation of a new Services Agreement.

 

Pursuant to communications between the Company and Darwin Fogt and Curtis Hollister regarding their resignations as executive officers and directors of the Registrant, which resignations were accepted by the Company’s Board on June 1, 2020, Messrs. Fogt and Hollister represented to the Company that Bistromatics and its management will continue to provide support services to the Company’s PHZIO System,. In addition, both Darwin Fogt and Curtis Hollister confirmed that they have had no disagreements with the operations, policies or practices of the Company.

 

In connection with the resignation of Darwin Fogt as CEO, the Registrant’s Board of Directors has appointed Douglas MacLellan, who has served as the Company’s Chairman since May 2013, as Chief Executive Officer in addition to continuing to serve as the Chairman of the Board of Directors.

 

As noted above, the Companies PHZIO and MSK360 systems are currently operated on behalf of the Company by Bistromatics Inc. in Canada. These services are still operational and continues to treat EWLL’s corporate patients and customers.

 

Plan of Operations

 

We are in the process of completing a new Services Agreement with Bistromatics, that if completed, will likely re-position EWLL as a Value Added Reseller (“VAR”) of the PHZIO & MSK360 platforms and allow EWLL to earn marketing fees and would also be granted a significant percentage ownership of Bistromatics in return for  transferring the marketing and IP rights for the PHZIO and MSK360 platforms from EWLL to Bistromatics.

 

15

 

 

IP and Licensing

 

We have licensed our telemedicine platform from Bistromatics Inc., a company owned by our CTO, for perpetuity for any telemedicine application in any market worldwide. The below noted chart highlights what we have built to date.

 

 

Results of Operations of eWellness for the three and six months ended June 30, 2020 vs. 2019

 

REVENUES: Total revenues for the six months ended June 30, 2020 and 2019 were $138,155 and $0. respectively. Total revenues for the three months ended June 30, 2020 and 2019 were $123,780 and $0, respectively.

 

OPERATING EXPENSES: Total operating expenses decreased to $1,659,824 for the six months ended June 30, 2020 from $2,028,493 for the six months ended June 30, 2019 reflecting a decrease of $368,669. The decrease resulted from a reduction in number of shares of common stock issued to consultants offset by an increase in financing fees for conversion of convertible debt. Total operating expenses decreased to $658,716 for the three months ended June 30, 2020 from $961,838 for the three months ended June 30, 2019 reflecting a decrease of $303,122. The decrease is a result of a decrease in the number of shares of common stock issued to consultants and offset by an increase in financing fees for conversion of convertible debt.

 

NET LOSS: The Company incurred a net loss $6,489,526 for the six months ended June 30, 2020 compared with a net loss of $3,103,781 for the six months ended June 30, 2019 which reflects an increase of $3,385,745. The increase is from an increase in loss on derivative liability on convertible debt of $4,817,926 offset by a decrease in interest expense of $929,239 and decrease in operating expenses of $368,669 (as outlined above). The Company incurred a net loss of $2,960,927 for the three months ended June 30, 2020, compared with a net loss of $1,765,310 for the three months ended June 30, 2019, which reflects an increase of $1,195,617. The increase is from an increase in loss on derivative liability on convertible debt of $2,155,621 offset by a decrease in interest expense of $536,974 and decrease in operating expenses of $303,122 (as outlined above).

 

Liquidity and Capital Resources

 

As of June 30, 2020, we had negative working capital of $8,114,425 compared to negative working capital of $6,937,847 as of December 31, 2019. The negative working capital increase is because of an increase in derivative liability, accounts payable and accrued expenses. Cash used in operations was $281,647 and $1,440,439 for the six months ended June 30, 2020 and 2019, respectively. The decrease in cash used in operations is a result of an increase in derivative liability and changes in operating assets and liabilities offset by an increase in net loss. Cash flows provided by financing activities were $45,000 and $1,140,300 for the six months ended June 30, 2020 and 2019, respectively. The decrease resulted from a decrease in the issuance of convertible debt (net of debt issuance costs) of $1,675,750 and reduction of payment of debt of $639,500. The cash balance as of June 30, 2020 was $4,075.

 

16

 

 

We do not have sufficient cash on hand to operate. We anticipate that we will be able to raise additional capital on the same or better terms by the third quarter of 2020 in the form of equity capital to provide the necessary working capital. Our ability to meet our obligations and continue to operate as a going concern is highly dependent on our ability to obtain additional financing. We cannot predict whether this additional financing will be in the form of equity or debt or be in another form. We may not be able to obtain the necessary additional capital on a timely basis, on acceptable terms, or at all. In any of these events, we may be unable to implement our current plans which circumstances would have a material adverse effect on our business, prospects, financial conditions and results of operations.

 

Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business.

 

Capital Expenditure Plan

 

During the six months ended June 30, 2020, we raised $52,800, less $7,800 for debt issuance costs in equity and debt capital. We will require up to an additional $1.6 million in capital during the next 12 months to fully implement our business plan and fund our operations. Our plan is to utilize the equity capital that we raise, together with anticipated cash flow from operations, to fund a very significant investment in sales and marketing, concentration principally on advertising and incentivizing existing customers for the introduction of new customers, among other strategies. However, there can be no assurance that: (i) we will continue to be successful in raising equity capital in sufficient amounts and/or at terms and conditions satisfactory to the Company; or (ii) we will generate sufficient revenues from operations, to fulfill our plan of operations. Our revenues are expected to come from our PHZIO platform services. As a result, we will continue to incur operating losses unless and until we are able to generate sufficient cash flow to meet our operating expenses and fund our planned sales and market efforts. There can be no assurance that the market will adopt our portal or that we will generate sufficient cash flow to fund our enhanced sales and marketing plan. In the event that we are not able to successfully: (i) raise equity capital and/or debt financing; or (ii) market and significantly increase the number of portal users and revenues from such users, our financial condition and results of operations will be materially and adversely affected and we will either have to delay or curtail our plan for funding our sales and marketing efforts.”

 

Off-Balance Sheet Arrangements

 

As of June 30, 2020 and December 31, 2019, respectively, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Securities Act of 1934.

 

Contractual Obligations and Commitments

 

Six Months Ended June 30, 2020

 

In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. The convertible note converts into common stock of the Company at a conversion price that shall be equal to the 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. During the six months ended June 30, 2020, the Company accrued interest expense of $1,719.

 

From time to time the Company may become a party to litigation matters involving claims against the Company. Except as may be outlined above, the Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

 

17

 

 

Critical Accounting Policies

 

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2019, for disclosures regarding the Company’s critical accounting policies and estimates, as well as any updates further disclosed in our interim financial statements as described in this Form 10-Q.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Smaller reporting companies are not required to provide this disclosure.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of disclosure controls and procedures.

 

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Based on that evaluation, our chief executive officer and chief financial officer concluded that, as of June 30, 2020, our disclosure controls and procedures were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules, regulations and forms, and (ii) that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in the Company’s internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

18

 

 

PART II - OTHER INFORMATION

 

ITEM 1. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

Six Months Ended June 30, 2020

 

During the six months ended June 30, 2020, the Company issued a total of 7,838,256,204 shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $959,835 of principal, $103,093 of accrued interest and $93,433 of financing costs.

 

During the six months ended June 30, 2020, the Company issued 668,332 shares of common stock for consultant services valued at $1,723.

 

19

 

 

ITEM 2 EXHIBITS

 

  (a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

 

Exhibit No.   Description
3.1(a)   Articles of Amendment to the Amended and Restated Articles of Incorporation, dated February 14, 2020 filed in the Company’s 10K for the period ended December 31, 2019.
3.2   Bylaws (Incorporated by reference to Exhibit 3(b) to the Registration Statement on Form S-1 filed on May 15, 2012)
31.1   Certification of CEO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2   Certification of CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1   Certification of CEO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2   Certification of CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

20

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

eWellness Healthcare Corporation    
(Registrant)    
       
By: /s/ Douglas MacLellan   Date August 11, 2020
  Douglas MacLellan    
  Chairman of the Board    

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Douglas MacLellan   Chairman of the Board and Director   August 11, 2020
Darin Fogt   (Principal Executive Officer)    
         
/s/ David Markowski   Chief Financial Officer and Director   August 11, 2020
David Markowski   (Principal Financial and Accounting Officer)    
         
/s/ Douglas Cole   Director   August 11, 2020
Douglas Cole        

 

21

 GRAPHIC 2 image_001.jpg begin 644 image_001.jpg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end GRAPHIC 3 form10-q_003.jpg begin 644 form10-q_003.jpg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�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ex31-1.htm

 

EXHIBIT 31.1

 

Exhibit 31.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation., pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Douglas MacLellan, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 of eWellness Healthcare Corporation (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made considering the circumstances made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2020  
   
/s/ Douglas MacLellan  
Douglas MacLellan  
Chairman of the Board (Principal Executive Officer)  

 

 
 EX-31.2 5 ex31-2.htm

 

EXHIBIT 31.2

 

Exhibit 31.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, David Markowski, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 of eWellness Healthcare Corporation (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2020  
   
/s/ David Markowski  
David Markowski,  
Chief Financial Officer  
(Principal Financial and Accounting Officer)  

 

 
 EX-32.1 6 ex32-1.htm

 

EXHIBIT 32.1

 

Exhibit 32.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended June 30, 2020 as filed with the Securities and Exchange Commission (the “Report”), the undersigned Darwin Fogt, Chief Executive Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  eWellness Healthcare Corporation.
     
Date: August 11, 2020 By: /s/ Douglas MacLellan
    Douglas MacLellan, Director and Chairman of the Board
    (Principal Executive Officer)

 

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 
 EX-32.2 7 ex32-2.htm

 

EXHIBIT 32.2

 

Exhibit 32.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended June 30, 2020 as filed with the Securities and Exchange Commission (the “Report”), the undersigned David Markowski, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  eWellness Healthcare Corporation
   
Date: August 11, 2020 /s/ David Markowski
  David Markowski, Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 

 EX-101.INS 8 ewll-20200630.xml XBRL INSTANCE FILE 0001550020 EWLL:ProgrammingCompanyMember 2016-11-01 2016-11-30 0001550020 EWLL:ProgrammingCompanyMember 2019-12-31 0001550020 2020-01-01 2020-06-30 0001550020 us-gaap:FairValueInputsLevel1Member 2020-06-30 0001550020 us-gaap:FairValueInputsLevel2Member 2020-06-30 0001550020 us-gaap:FairValueInputsLevel3Member 2020-06-30 0001550020 2020-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MinimumMember 2020-06-30 0001550020 EWLL:DerivativeLiabilityMember srt:MaximumMember 2020-06-30 0001550020 EWLL:ProgrammingCompanyMember 2016-11-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2020-01-01 2020-06-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2020-01-01 2020-06-30 0001550020 us-gaap:PreferredStockMember 2018-12-31 0001550020 us-gaap:CommonStockMember 2018-12-31 0001550020 EWLL:SharesToBeIssuedMember 2018-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001550020 us-gaap:RetainedEarningsMember 2018-12-31 0001550020 EWLL:DerivativeLiabilityMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-06-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-06-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2020-06-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2020-06-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-06-30 0001550020 2019-12-31 0001550020 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001550020 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001550020 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001550020 EWLL:OfficersAndDirectorsMember 2019-12-31 0001550020 us-gaap:PreferredStockMember 2019-12-31 0001550020 us-gaap:CommonStockMember 2019-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001550020 us-gaap:RetainedEarningsMember 2019-12-31 0001550020 EWLL:DerivativeLiabilityMember 2020-06-30 0001550020 EWLL:NotesMember 2020-01-01 2020-06-30 0001550020 EWLL:NotesMember 2019-12-31 0001550020 EWLL:OfficersDirectorsAndConsultantsMember 2019-12-31 0001550020 EWLL:EquityPurchaseAgreementMember EWLL:CapitalCallMember 2019-04-01 2019-04-02 0001550020 EWLL:SharesToBeIssuedMember 2019-01-01 2019-06-30 0001550020 EWLL:SharesToBeIssuedMember 2019-12-31 0001550020 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001550020 us-gaap:PreferredStockMember 2019-06-30 0001550020 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001550020 us-gaap:CommonStockMember 2019-06-30 0001550020 EWLL:SharesToBeIssuedMember 2019-04-01 2019-06-30 0001550020 EWLL:SharesToBeIssuedMember 2019-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001550020 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001550020 us-gaap:RetainedEarningsMember 2019-06-30 0001550020 2019-04-01 2019-06-30 0001550020 2019-03-31 0001550020 EWLL:PhysicalTherapyMarketMember 2020-01-01 2020-06-30 0001550020 EWLL:MusculoskeletalTreatmentMember 2020-01-01 2020-06-30 0001550020 EWLL:WellnessIndustryMember 2020-01-01 2020-06-30 0001550020 us-gaap:PreferredStockMember 2019-01-01 2019-06-30 0001550020 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001550020 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001550020 2019-01-01 2019-06-30 0001550020 2019-06-30 0001550020 EWLL:ConvertibleNoteOneMember 2020-01-01 2020-06-30 0001550020 EWLL:ConvertibleNoteOneMember 2020-06-30 0001550020 2019-12-15 2019-12-16 0001550020 us-gaap:PreferredStockMember 2020-01-01 2020-06-30 0001550020 us-gaap:PreferredStockMember 2020-06-30 0001550020 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001550020 us-gaap:CommonStockMember 2020-06-30 0001550020 EWLL:SharesToBeIssuedMember 2020-01-01 2020-06-30 0001550020 EWLL:SharesToBeIssuedMember 2020-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001550020 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001550020 us-gaap:RetainedEarningsMember 2020-06-30 0001550020 2018-12-31 0001550020 EWLL:OfficersAndDirectorsMember 2020-06-30 0001550020 2019-01-01 2019-12-31 0001550020 EWLL:NotesMember 2020-06-30 0001550020 EWLL:CommonStockOneMember EWLL:BoardOfDirectorsMember 2020-02-10 2020-02-12 0001550020 EWLL:CommonStockTwoMember 2020-02-14 0001550020 EWLL:ConsultantMember 2020-01-01 2020-06-30 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-01 2020-01-31 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember EWLL:MonthlyMember 2020-01-01 2020-01-31 0001550020 EWLL:CommonStockTwoMember 2020-06-30 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-31 0001550020 EWLL:ProgrammingCompanyMember 2020-06-30 0001550020 EWLL:CommonStockOneMember EWLL:BoardOfDirectorsMember 2019-01-01 2019-12-31 0001550020 EWLL:DerivativeLiabilityMember 2020-01-01 2020-06-30 0001550020 EWLL:DerivativeLiabilityMember 2019-01-01 2019-06-30 0001550020 EWLL:FormerChiefExecutiveOfficerMember 2020-06-30 0001550020 2020-04-01 2020-06-30 0001550020 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0001550020 us-gaap:PreferredStockMember 2020-03-31 0001550020 us-gaap:PreferredStockMember 2019-03-31 0001550020 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001550020 us-gaap:CommonStockMember 2020-03-31 0001550020 us-gaap:CommonStockMember 2019-03-31 0001550020 EWLL:SharesToBeIssuedMember 2020-04-01 2020-06-30 0001550020 EWLL:SharesToBeIssuedMember 2020-03-31 0001550020 EWLL:SharesToBeIssuedMember 2019-03-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001550020 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001550020 us-gaap:RetainedEarningsMember 2020-03-31 0001550020 us-gaap:RetainedEarningsMember 2019-03-31 0001550020 EWLL:BistromaticsIncMember EWLL:ServicesAgreementMember 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-01 2020-03-31 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesDPreferredStockMember 2020-04-30 0001550020 2020-04-30 0001550020 us-gaap:SeriesDPreferredStockMember 2020-04-01 2020-04-30 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-01 2020-06-30 0001550020 EWLL:AprilTwoThousandAndEighteenForTwelveMonthMember EWLL:ConsultingServicesMember 2019-02-06 2019-02-07 0001550020 us-gaap:InvestorMember 2019-03-20 2019-03-22 0001550020 EWLL:ConsultingServicesMember 2019-05-16 2019-05-17 0001550020 EWLL:ConsultingAgreementMember EWLL:ConsultantMember 2019-01-01 2019-06-30 0001550020 us-gaap:SubsequentEventMember 2020-08-14 0001550020 us-gaap:SubsequentEventMember 2020-07-01 2020-08-14 0001550020 EWLL:ConsultingServicesMember 2019-04-01 2019-06-30 0001550020 EWLL:BistromaticsIncMember EWLL:ServicesAgreementMember 2016-11-11 2016-11-12 0001550020 2020-03-31 0001550020 2020-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure EWLL:Integer .001 .001 0.001 20000000 20000000 1000000 200000 0.001 0.001 476667 250000 476667 250000 20000000000 20000000000 1900000000 20000000000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the status of all Company&#8217;s stock options as of June 30, 2020 and changes during the six months ended on that date:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number<br /> of Stock</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Average<br /> Exercise</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Intrinsic</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Life (yrs)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Value</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2019</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40.00</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.1</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2020</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40.00</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">.6</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable at June 30, 2020</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40.00</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">.6</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1. The Company</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>The Company and Nature of Business</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">eWellness Healthcare Corporation (the &#8220;eWellness&#8221;, &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) was incorporated in the State of Nevada on April 7, 2011. The Company has generated minimal revenues to date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. Our business model is to have large-scale employers use our PHZIO platform as a fully PT monitored corporate musculoskeletal treatment (&#8220;MSK&#8221;) wellness program. The Company&#8217;s PHZIO home physical therapy assessment and exercise platform has been designed to disrupt the $30 billion physical therapy market, the $4 billion MSK market and the $8 billion corporate wellness industry. PHZIO re-defines the way MSK physical therapy can be delivered. PHZIO is the first real-time remote monitored 1-to-many MSK physical therapy platforms for home use.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 22, 2020, the Company received and accepted the resignations of Brandon Rowberry and Rochelle Pleskow as independent directors. Their letters of resignation state the reason for their resignations were to permit them to pursue other business opportunities and further stated that they have had no disagreements with the operations, policies or practices of the Company. Also, on May 22, 2020, the Company received a letter of resignation from Darwin Fogt resigning as CEO, President and director of the Company and a separate letter of resignation from Curtis Hollister, resigning as CTO and director of the Company. Messrs. Fogt and Hollister are executive officers and principals of Bistromatics Inc., organized under the laws of Canada (&#8220;Bistromatics&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 12, 2016, the Company entered into a Services Agreement with Bistromatics (the &#8220;Bistromatics Agreement&#8221;) pursuant to which Bistromatics agreed to provide operational services to the Company for its PHZIO System including development, content editing and training, support and maintenance, billing, hosting and oversight, among other services. Reference is made to the Company&#8217;s Form 8-K filed on November 21, 2016, which Form 8-K was signed by Darwin Fogt as CEO on behalf of the Company, regarding the disclosure of the Bistromatics Agreement. The Services Agreement included a provision granting Bistromatics the right to appoint 40% of the Registrant&#8217;s Board of Directors, resulting in the appointment of Messrs. Fogt and Hollister as members of the Company&#8217;s Board. Although both Companies continue to abide by the Services Agreement the Company is in arrears in fees to Bistromatics for approximately $750,000 as of March 31, 2020. The Service Agreement expired during the 1<sup>st</sup> quarter of 2020 and the parties continue to discuss the formation of a new Services Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to communications between the Company and Darwin Fogt and Curtis Hollister regarding their resignations as executive officers and directors of the Company, which resignations were accepted by the Company&#8217;s Board on June 1, 2020, Messrs. Fogt and Hollister represented to the Company that Bistromatics and its management will continue to provide support services to the Company&#8217;s PHZIO System, In addition, both Darwin Fogt and Curtis Hollister confirmed that they have had no disagreements with the operations, policies or practices of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the resignation of Darwin Fogt as CEO, the Registrant&#8217;s Board of Directors has appointed Douglas MacLellan, who has served as the Company&#8217;s Chairman since May 2013, as Chief Executive Officer in addition to continuing to serve as the Chairman of the Board of Directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted above, the Companies PHZIO and MSK360 systems are currently operated on behalf of the Company by Bistromatics Inc. in Canada. These services are still operational and continues to treat EWLL&#8217;s corporate patients and customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are in the process of completing a new Services Agreement with Bistromatics, that, when completed, will likely re-position EWLL as a Value Added Reseller (&#8220;VAR&#8221;) of the PHZIO &#38; MSK360 platforms and allow EWLL to earn marketing fees and would also be granted a significant percentage ownership of Bistromatics in return for &#160;transferring the marketing and IP rights for the PHZIO and MSK360 platforms from EWLL to Bistromatics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2. Summary of Significant Accounting Policies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basis of Presentation</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2020 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2020. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information regarding common stock shares, options and warrants throughout this document have been adjusted to reflect the 1:50 reverse split authorized by the Board of Directors on December 16, 2019 and further approved by FINRA on February 12, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Going Concern</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the six months ended June 30, 2020, the Company had revenues of $138,155. The Company has an accumulated loss of $37,351,545 and a working capital deficit of $8,114,425. In view of these matters, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s ability to continue operations is dependent upon the Company&#8217;s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Derivative Liability</font></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total Liabilities measured at fair value</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Derivative Liability</font></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total Liabilities measured at fair value</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3. Related Party Transactions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2016, the Company signed an agreement with a programming company (&#8220;PC&#8221;) within which one of the Company&#8217;s former directors and Chief Technical Officer (&#8220;CTO&#8221;) is the Chief Marketing Officer. The agreement is for additional features to be programmed for the launch of the PHZIO platform. The Company is to pay a monthly base fee of $100,000 for the development and compensation for the Company&#8217;s CEO and CTO. Following payment of the initial $100,000, the Company is obligated to only pay $50,000 monthly until the PC has successfully signed and collected the first monthly service fee for 100 physical therapy clinics to use the PHZIO platform. The PC will also have the right to appoint 40% of the directors. At the periods ended June 30, 2020 and December 31, 2019, the Company had a payable of $782,832 and $582,832, respectively. The CTO resigned his officer and director position on June 1, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company signed an agreement with the former CEO for administrative physical therapy consulting. The agreement provides that the former CEO will provide non-clinical administrative services in the various states where the Phzio companies are located. The Company is to pay the former CEO the sum of $3,500 per month. Since the former CEO resigned his officer and director position on June 1, 2020, any amounts owed to him are included in accounts payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Throughout the six months ended June 30, 2020, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of June 30, 2020 and December 31, 2019 were $0 and $1,368, respectively. There were no expenses due to the board members, but the Company has accrued directors&#8217; fees of $121,107 and $137,500 as of June 30, 2020 and December 31, 2019, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $357,965 and $532,974 as of June 30, 2020 and December 31, 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4. Convertible Notes Payable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Six Months Ended June 30, 2020</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. During the six months ended June 30, 2020, the Company accrued interest expense of $1,719.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5. Equity Transactions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Preferred Stock</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The total number of shares of preferred stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $0.001 per share. During the year ended December 31, 2019, the Company authorized the issuance of 1,000,000 shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $3,000,000 and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two directors resigned and on June 1, 2020, three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. During the six months ended June 30, 2020, there were 226,667 preferred shares that vested and $297,500 was recorded to reduce accrued compensation; $37,250 was recorded to reduce accrued directors&#8217; fees, and $345,250 was recorded as expense for a total of $680,000. As of June 30, 2020, there were 476,667 vested preferred shares for a total value of $1,430,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2020, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series D Preferred Stock in which the Board authorized a new series of Preferred Stock to be designated as Series D. The Board authorized two hundred thousand (200,000) shares to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Series D Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation&#8217;s Common Stock, par value $0.001 per share (&#8220;Common Stock&#8221;), and to all other equity securities issued by the Corporation other than the Corporation&#8217;s newly authorized 13% Series B Cumulative Redeemable Perpetual Preferred Stock (the &#8220;Series B Preferred&#8221;); (ii) on parity with all equity securities issued by the Corporation with terms specifically providing that the Series B Preferred ranks on parity, except with respect to voting rights on which the Series B Preferred ranks junior to the Series D Preferred and except with respect to rights to the payment of dividends and the distribution of assets upon any liquidation, dissolution or winding up of the Corporation, which the Series B Preferred ranks senior to the Series D Preferred; and (iii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others in) existing subsidiaries of the Corporation. The term &#8220;equity securities&#8221; shall not include convertible debt securities The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Common Stock</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 12, 2020, FINRA approved a 1:50 reverse split of the Company&#8217;s common stock. As noted throughout this document, all common shares are stated as if the 1:50 reverse split had been completed as of the beginning of the year ended December 31, 2019. Following the approval, the Company&#8217;s stock began trading under the symbol &#8220;EWLLD&#8221;. Due to rounding issues for the reverse split, the Company issued 47,876 additional shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (1,900,000,000) shares of Common Stock to twenty billion (20,000,000,000) shares of Common Stock. On February 19, 2019, the Company filed Articles of Amendment to the Company&#8217;s Articles of Incorporation to implement the Authorized Common Stock Share Increase with the State of Nevada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Six Months Ended June 30, 2020</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 shares of common stock monthly. The Company issued 80,000 shares of common stock with a value of $126. The Company needs to issue an additional 40,000 shares of common stock with a value of $8. In addition, the Company is to also pay the advisor a monthly fee of $2,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended June 30, 2020, the Company issued a total of 7,838,256,204 shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $959,835 of principal, $103,093 of accrued interest and $93,433 of financing costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended June 30, 2020, the Company issued 588,332 shares of common stock for consultant services valued at $1,597.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Six Months Ended June 30, 2019</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 7, 2019, the Company executed an amendment to a contract executed on April 8, 2018 for twelve months for consulting services. The Company issued 5,000 shares of common stock at the signing of the contract valued at $30,500 that is being amortized over the life of the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 22, 2019, the Company issued 65,217 shares of common stock to an institutional investor as part of a promissory note. These shares are returnable if the Company repays the promissory note before the maturity date. The value of these shares is $375,000 which was recorded as prepaid until the six-month maturity has passed. The Company also issued 20,000 shares of common stock to the institutional investor as a commitment fee. The value of these shares is $115,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 2, 2019, the Company issued 16,000 shares of common stock pursuant to a capital call notice in relation to an Equity Purchase Agreement dated June 18, 2018. The capital call totaled $59,100.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 17, 2019, the Company executed a contract for three months for consulting services. The Company issued 10,000 shares of common stock at the signing of the contract valued at $53,000 that is being amortized over the life of the contract. At the end of the three months, the Company is to issue another 10,000 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended June 30, 2019, the Company issued 59,500 shares of common stock to consultants for services rendered in accordance to consulting agreements. The value of these shares is $339,633.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended June 30, 2019, the Company issued 125,574 shares of common stock for debt conversion totaling $401,242 which includes $380,250 principal, $18,992 accrued interest and $2,000 due diligence fee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Stock Options</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the status of all Company&#8217;s stock options as of June 30, 2020 and changes during the six months ended on that date:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number<br /> of Stock</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Average<br /> Exercise</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Intrinsic</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Life (yrs)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Value</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2019</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40.00</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.1</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2020</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40.00</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">.6</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable at June 30, 2020</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">57,000</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40.00</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">.6</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Warrants</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the status of the Company&#8217;s warrants as of June 30, 2020 and changes during the six months ended on that date:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Average<br /> Exercise</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Intrinsic</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Life (yrs.)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Value</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2019</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">42,015</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11.94</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.9</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(10,000</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17.50</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2020</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">32,015</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10.20</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.0</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercisable at June 30, 2020</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">32,015</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10.20</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.0</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6. Commitments, Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The Company believes that there are no current matters that would have a material effect on the Company&#8217;s financial position or results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8. Subsequent Events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From July 1 until the filing of this report, the Company issued 880,679,972 shares of common stock for convertible debt conversion totaling $54,322 which includes $50,362 principal and $3,960 accrued interest</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basis of Presentation</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2020 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2020. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information regarding common stock shares, options and warrants throughout this document have been adjusted to reflect the 1:50 reverse split authorized by the Board of Directors on December 16, 2019 and further approved by FINRA on February 12, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Going Concern</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the six months ended June 30, 2020, the Company had revenues of $138,155. The Company has an accumulated loss of $37,351,545 and a working capital deficit of $8,114,425. In view of these matters, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s ability to continue operations is dependent upon the Company&#8217;s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Derivative Liability</font></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total Liabilities measured at fair value</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Derivative Liability</font></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total Liabilities measured at fair value</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Derivative Liability</font></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total Liabilities measured at fair value</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Derivative Liability</font></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total Liabilities measured at fair value</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Stock price at valuation date</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">.0002</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Exercise price of warrants</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">12.50</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Conversion rate of convertible debt</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">.00007-.00014</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Risk free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">.10%-.27</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Stock volatility factor</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">347.96-1322.92</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Years to Maturity</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">.02 &#8211; .55</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Expected dividend yield</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">None</font></td> <td></td></tr> </table> 33009 59500 668332 588332 253332 5000 10000 59500 10000 785 33 158051 158084 60 339573 339633 668 -74 191 1597 128 253 76 -201 30500 53000 339633 7851724496 12752084 7851724496 12752084 eWELLNESS HEALTHCARE Corp 10-Q 2020-06-30 false --12-31 Non-accelerated Filer 2020 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7. Derivative Valuation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, &#8220;Derivatives and Hedging,&#8221; and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The debt discount is amortized over the life of the note and recognized as interest expense. For the six months ended June 30, 2020 and 2019, the Company amortized the debt discount of $594,705 and $1,401,501, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended June 30, 2020, the Company had the following activity in the derivative liability account:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Notes</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font: 10pt Times New Roman, Times, Serif">Derivative liability at December 31, 2019</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 14%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,529,974</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Addition of new conversion option derivatives</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Conversion of note derivatives</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,432,496</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Change in fair value</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,199,959</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Derivative liability at June 30, 2020</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,297,437</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%"><font style="font: 10pt Times New Roman, Times, Serif">Stock price at valuation date</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">.0002</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exercise price of warrants</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12.50</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Conversion rate of convertible debt</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">.00007-.00014</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">.10%-.27</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Stock volatility factor</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">347.96-1322.92</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Years to Maturity</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">.02 &#8211; .55</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend yield</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">None</font></td> <td>&#160;</td></tr> </table> 21763 157139 155710 401496 16268 22810 8000 9000 179978 433306 733025 314287 782832 582832 121107 138868 357965 532974 1977769 2240408 4297437 3529974 8270135 7339343 8270135 7339343 477 250 1430000 7851725 12752 21409110 23942830 -37351545 -30862019 725250 1736987 594705 1401501 4075 240722 true false 0001550020 false Yes Yes 4075 240722 82655 383335 76 150 Q2 179978 433306 129872 3635 30000000000 4000000000 8000000000 PHZIO is the first real-time remote monitored 1-to-many MSK physical therapy platforms for home use. 50:1 split 1:50 reverse split 1:50 reverse split 1:50 reverse split 4297437 4297437 3529974 3529974 4297437 4297437 3529974 3529974 2500 100000 2500 50000 The agreement is for additional features to be programmed for the launch of the PHZIO platform. The Company is to pay a monthly base fee of $100,000 for the development and compensation for the Company's CEO and CTO. Following payment of the initial $100,000, the Company is obligated to only pay $50,000 monthly until the PC has successfully signed and collected the first monthly service fee for 100 physical therapy clinics to use the PHZIO platform. The PC will also have the right to appoint 40% of the directors. 582832 1368 0 782832 121107 137500 3500 357965 532974 23629 125574 7838256204 7838256204 6421465710 65217 880679972 1156361 24 53732 53756 125 401117 401242 7838257 -6681896 373817 6421466 -6047649 375000 54322 16000 16000 16000 80000 20000 47876 40000 59100 16 59084 59100 16 59084 59100 126 8 1719 3960 380250 959835 52800 50362 0.00007 0.00014 93433 12.50 57000 57000 40.00 40.00 P1Y1M6D P0Y7M6D P0Y7M6D 0.0002 3529974 4297437 4199959 4199959 0.10 0.27 347.96 1322.92 0.00 P7D P6M18D The term "equity securities" shall not include convertible debt securities The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time. 0.13 20000 115000 57000 40.00 32015 42015 32015 10.20 11.94 10.20 P1Y P1Y P1Y10M25D 17.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of the status of the Company&#8217;s warrants as of June 30, 2020 and changes during the six months ended on that date:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Number of</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Average<br /> Exercise</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Intrinsic</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Life (yrs.)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Value</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2019</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">42,015</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11.94</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.9</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(10,000</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17.50</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at June 30, 2020</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">32,015</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10.20</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.0</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercisable at June 30, 2020</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">32,015</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10.20</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.0</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> </table> 8732404469. 2672747473 219592981 215560585 5181476648 -0.00 -0.01 -0.01 -0.00 -6489526 -1765310 -3103781 -2960927 764033 742047 1693272 205073 -3866 -3866 -4199959 -61431 617967 -2217052 1 6 17 -1521669 -961838 -2028493 -534936 1659824 961838 2028493 658716 850581 534980 1249141 383163 435243 324858 575352 88553 374000 102000 204000 187000 138155 123780 4128139 250000 12752084 4429430 476667 7851724496 375000 1430005454 4346792 -8090157 4128 17416117 -21401234 -6906037 250 12752 23942830 -30862019 150 4429 19460868 -24505015 -3723334 -5039718 477 7851725 76 21409110 -37351545 -3980989 375 1430006 4346 26285825 19012024 -34390618 -22739705 -6674412 108000 54000 54000 108000 108000 108000 54000 54000 226667 101667 680000 227 679773 305000 102 304898 3360260 70987 70987 563327 563327 3360260 812237 812237 -6489526 -1765310 -1765310 -3103781 -3103781 -6489526 -2960927 -2960927 10000 80217 10 52990 53000 80 458670 458750 47876 48 -48 20000 20 114980 115000 -281647 -1440439 122491 -43279 31509 -13560 196460 -9981 513643 83297 126237 9916 37628 93433 115000 785 339633 344960 108000 108000 3676 2840 -541 541 -236647 -300680 45000 1140300 7800 248150 639550 52800 1968900 59100 458750 1156360 401242 1769048 275814 1856 8114425 2021-01-15 3000 0.70 10 0.12 4800 40 The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. 3000000 226667 297500 37250 345250 680000 2000 10000 750000 Bistromatics agreed to provide operational services to the Company for its PHZIO System including development, content editing and training, support and maintenance, billing, hosting and oversight, among other services. Reference is made to the Company's Form 8-K filed on November 21, 2016, which Form 8-K was signed by Darwin Fogt as CEO on behalf of the Company, regarding the disclosure of the Bistromatics Agreement. The Services Agreement included a provision granting Bistromatics the right to appoint 40% of the Registrant's Board of Directors, resulting in the appointment of Messrs. Fogt and Hollister as members of the Company's Board. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended June 30, 2020, the Company had the following activity in the derivative liability account:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Notes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%"><font style="font-size: 10pt">Derivative liability at December 31, 2019</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">3,529,974</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Addition of new conversion option derivatives</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Conversion of note derivatives</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(3,432,496</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Change in fair value</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4,199,959</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Derivative liability at June 30, 2020</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,297,437</font></td> <td style="padding-bottom: 2.5pt"></td></tr> </table> After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. 476667 18992 103093 0.40 0.40 EX-101.SCH 9 ewll-20200630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Reconciliation of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Condensed Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments, Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Derivative Valuation link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Derivative Valuation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - The Company (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Equity Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equity Transactions - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Equity Transactions - Summary of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Derivative Valuation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Derivative Valuation - Schedule of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 ewll-20200630_cal.xml XBRL CALCULATION FILE EX-101.DEF 11 ewll-20200630_def.xml XBRL DEFINITION FILE EX-101.LAB 12 ewll-20200630_lab.xml XBRL LABEL FILE Related Party Transactions By Related Party [Axis] Programming Company [Member] Fair Value, Hierarchy [Axis] Level 1 [Member] Level 2 [Member] Level 3 [Member] Award Type [Axis] Derivative Liability [Member] Range [Axis] Minimum [Member] Maximum [Member] Valuation Approach and Technique [Axis] Valuation Technique, Option Pricing Model [Member] Measurement Input Type [Axis] Years to Maturity [Member] Statement Equity Components [Axis] Preferred Shares [Member] Common Stock [Member] Shares to be Issued [Member] Additional Paid in Capital [Member] Accumulated Deficit [Member] Risk Free Interest Rate [Member] Stock Volatility Factor [Member] Expected Dividend Yield [Member] Title of Individual [Axis] Officers and Directors [Member] Derivative Instrument [Axis] Notes [Member] Officers, Directors and Consultants [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Equity Purchase Agreement [Member] Capital Call [Member] Legal Entity [Axis] Physical Therapy Market [Member] MSK [Member] Wellness Industry [Member] Debt Instrument [Axis] Convertible Notes One [Member] Common Stock One [Member] Board of Directors [Member] Common Stock Two [Member] Consultant [Member] 12- month Advisory Services Agreement [Member] Scenario [Axis] Monthly [Member] Former CEO [Member] Bistromatics Inc. [Member] Services Agreement [Member] 12% Convertible Promissory Note [Member] Class of Stock [Axis] Series D Preferred Stock [Membe Series D Preferred Stock [Member] April 2018 for Twelve Months [Member] Consulting Services [Member] Investor [Member] Consulting Agreement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Accounts Receivable Prepaid expenses Total current assets Property & equipment, net Intangible assets, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Accounts payable and accrued expenses Accounts payable - related party Accrued expenses - related party Accrued compensation Convertible debt, net of discount Derivative liability Total current liabilities Total Liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' DEFICIT Preferred stock, authorized 20,000,000 shares, $.001 par value, 476,667 and 250,000 shares issued and outstanding, respectively Common stock, authorized 20,000,000,000 shares, $.001 par value, 7,851,724,496 and 12,752,084 issued and outstanding, respectively Shares to be issued Additional paid in capital Accumulated deficit Total Stockholders' Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] REVENUE OPERATING EXPENSES Executive compensation General and administrative Professional fees Total Operating Expenses Loss from Operations OTHER INCOME (EXPENSE) Interest income Gain (loss) on derivative liability Loss on disposal of asset Interest expense Net Loss before Income Taxes Income tax expense Net Loss Basic and diluted (loss) per share Weighted average shares outstanding Statement [Table] Statement [Line Items] Equity Components [Axis] Balance Balance, shares Contributed services Shares issued for debt conversion Shares issued for debt conversion, shares Shares issued for cash Shares issued for cash, shares Shares issued for financing costs Shares issued for financing costs, shares Shares issued for prepaid services Shares issued for prepaid services, shares Shares issued for services Shares issued for services, shares Derivative liability Shares issued to officers, directors and consultants Shares issued to officers, directors and consultants, shares Shares issued for rounding - 50:1 split Shares issued for rounding - 50:1 split, shares Net loss Balance Balance, shares Statement of Stockholders' Equity [Abstract] Reverse stock split, description Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Contributed services Shares issued for officers, directors and consultants Shares issued for consulting services Shares issued for financing costs Amortization of debt discount and prepaids (Gain) loss on derivative liability Loss on disposal of asset Changes in operating assets and liabilities Prepaid expense Accounts receivable Accounts payable and accrued expenses Accounts payable - related party Accrued expenses - related party Accrued compensation Net cash used in operating activities Cash flows from investing activities Purchase of equipment Net cash used in investing activities Cash flows from financing activities Proceeds from issuance of common stock Issuance of convertible debt Payments on debt Debt issuance costs Net cash provided by financing activities Net increase (decrease) in cash Cash, beginning of period Cash, end of period Supplemental Information: Cash paid for: Taxes Interest Expense Non cash items: Derivative liability and debt discount issued with new notes Shares issued for debt conversion Shares issued for prepaids Organization, Consolidation and Presentation of Financial Statements [Abstract] The Company Accounting Policies [Abstract] Summary of Significant Accounting Policies Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Convertible Notes Payable Equity [Abstract] Equity Transactions Commitments and Contingencies Disclosure [Abstract] Commitments, Contingencies Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Valuation Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Going Concern Fair Value of Financial Instruments Summary of Assets and Liabilities Fair Value on Recurring Basis Summary of Stock Options Activity Summary of Warrants Activity Schedule of Derivative Liability Schedule of Assumptions Used Black Scholes Valuation of Derivative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Physical therapy assessment and exercise platform Physical therapy investment, description Agreement description Percentage of rights in appointment of director Arrears in fees amount Revenues Working capital deficit Fair Value Hierarchy and NAV [Axis] Derivative Liability Total Liabilities measured at fair value Related Party [Axis] Monthly base fee Related party transaction, description of transaction Fee payable per month Due to related party Accrued directors' fees Accrued executive compensation Debt face amount Debt interest stated rate Debt maturity date Original issue discount Transaction costs Convertible debt percentage Number of trading days Convertible notes, description Accrued interest Conversion of stock, shares Conversion of stock, description Deferred compensation Vested preferred shares Stock option expense Accrued directors fees Expenses Total expenses Number of vested preferred shares Preferred stock, value Newly authorized redeemable preferred stock percentage Preferred stock voting rights Stock issued during the period Stock issued during the period, value Principal amount Accrued interest Financing costs Shares issued during period for services, shares Shares issued during period for services, value Debt conversion of common stock value Shares issued during period commitment fee, shares Shares issued during period commitment fee Diligence fee Number of Stock Options Outstanding, Beginning Balance Number of Stock Options Outstanding, Granted Number of Stock Options Outstanding, Exercised Number of Stock Options Outstanding, Cancelled Number of Stock Options Outstanding, Ending Balance Number of Stock Options exercisable, Ending Balance Weighted Average Exercise Price Outstanding, Beginning Balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price Outstanding, Ending Balance Weighted Average Exercise Price Options exercisable, Ending Balance Remaining Life (yrs) Outstanding, Beginning Balance Remaining Life (yrs) Outstanding, Ending Balance Remaining Life (yrs) Options exercisable, Ending Balance Intrinsic Value Outstanding, Beginning Balance Intrinsic Value Outstanding, Ending Balance Intrinsic Value Options exercisable, Ending Balance Number of Warrants, Outstanding, Beginning Balance Number of Warrants, Granted Number of Warrants, Exercised Number of Warrants, Cancelled Number of Warrants, Outstanding, Ending Balance Number of Warrants, exercisable, Ending balance Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance Weighted Average Exercise Price, Warrants Granted Weighted Average Exercise Price, Warrants Exercised Weighted Average Exercise Price, Warrants Cancelled Weighted Average Exercise Price, Warrants Outstanding, Ending Balance Weighted Average Exercise Price Exercisable, Ending Balance Remaining Life (yrs.) Warrants Outstanding, Beginning Balance Remaining Life (yrs.) Warrants Outstanding, Ending Balance Remaining Life (yrs.) Warrants Exercisable, Ending Balance Intrinsic Value, Warrants Outstanding, Beginning Balance Intrinsic Value, Warrants Granted Intrinsic Value, Warrants Exercised Intrinsic Value, Warrants Cancelled Intrinsic Value, Warrants Outstanding, Ending Balance Intrinsic Value, Warrants Exercisable, Ending Balance Amortized of debt discount Derivative liability, beginning balance Addition of new conversion option derivatives Conversion of note derivatives Change in fair value Derivative liability, ending balance Statistical Measurement [Axis] Stock price at valuation date Exercise price of warrants Conversion rate of convertible debt Derivative liability, fair value measurement input percentage Derivative liability, term Accredited Investor [Member] Accrued liabilities related parties current. Addition of new conversion option derivatives. Adjustments To Additional Paid In Capital Contributed Services. Advisory Agreement [Member] Advisory Services Agreement [Member] After Signing Date [Member] Agreement with Consultant [Member] At Signing [Member] custom:BoardOfDirectorsMember California [Member] California or Louisiana [Member] Note Payable, Accrued Interest and Warrants [Member] Cashless Warrant [Member] Certificate of Amendment [Member] Commitment Fee [Member] Common Stock One [Member] Common Shares (Services) [Member] Common Stock Two [Member] Consultant [Member] Consultants [Member] Consulting Agreement [Member] Consulting and Marketing Services [Member] Consulting Firm [Member] Consulting Service Member. Consulting services agreement [Member] Consulting Services [Member] Contributed services. Conversion of note derivatives. Convertible Debt Holder [Member]. Convertible Note Dated December 7, 2015 [Member] Convertible Note Dated November 14, 2016 [Member] Convertible Note [Member] Convertible Notes One [Member] Convertible Note Two [Member] Convertible Notes [Member] Convertible Notes Payable [Member] Convertible Notes [Member] Convertible Promissory Note [Member] Convertible Promissory Notes [Member] Convertible Promissory Notes [Member] Convertible Notes Redeemable Back End Note [Member] Debt Agreement [Member] December 7, 2015 Convertible Notes Payable [Member] December 23, 2014 Convertible Notes Payable [Member] Definitive Service Agreement [Member] Definitive Service Agreement [Member] Definitive Services Agreement [Member] Derivative liability. Derivative liability and debt discount issued with new notes. Derivative Liability [Member] Accrued directors fees. Discount on common stock membr. Effect of Filing of Certificate of Amendment [Member] 8% Convertible Promissory Back-End Note [Member] 8% Convertible Promissory Note Five [Member] 8% Convertible Promissory Note Four [Member] 8% Fixed Convertible Promissory Note [Member] 8% Convertible Promissory Note One [Member] 8% Convertible Promissory Note Seven [Member] 8% Convertible Promissory Note Six [Member] 8% Convertible Promissory Note Three [Member] 8% Convertible Promissory Note Two [Member] 8% Fixed Convertible Promissory Note Four [Member] 8% Fixed Convertible Promissory Note 8% Fixed Convertible Promissory Note 1 [Member] 8% Fixed Convertible Promissory Note Two [Member] 8% Fixed Convertible Promissory Note [Member] Equity Incentive Plan [Member] Equity Purchase Agreement [Member] Escrow Trust [Member] Extension Agreement [Member] Extension Agreement One [Member] February 9, 2017 [Member] Fee payable per month. Financing Agreement [Member] First Extension Agreement [Member] First Note [Member] First Tranche At Signing Date [Member] First Tranche [Member] First Tranche On Signing Date [Member] Former Secretary-Treasurer and CFO [Member] Forty-Five (45) Days After the Second Closing Date [Member] Forty-Five (45) Days After Signing Date [Member] Fourth Tranche [Member] Going concern [Policy Text Block] Increase Decrease in Accrued Liabilities Related Parties. Increased Values [Member] Institutional Investor [Member] January [Member] July 2018 [Member] Management and Board of Directors [Member] March 31, 2019 [Member] March 3, 2018 [Member] Marketing and Consulting Services [Member] Marketing Services [Membe] Mavericks Capital Securities Llc [Member] Mr. Mills [Member] MSK [Member]. Non-Convertible Notes Payable 5 [Member] Non-Convertible Notes Payable 4 [Member] Non-Convertible Notes Payable [Member] Non-Convertible Notes Payable [Member] Non-Convertible Notes Payable 6 [Member] Non-Convertible Notes Payable [Member] Non-Convertible Notes Payable [Member] Note Holder [Member] Note [Member] Notes [Member] Notes Payable [Member] Officers and Directors [Member]. Officers,Directors and Consultants [Member] Officers [Member] Options [Member] Physical therapy assesment and exercise platform. Physical therapy investment, description. Physical Therapy Market [Member]. Programming Company [Member] Promissory Note [Member] Promissory Notes Dated December 15, 2014, March 14, 2016 and May 1, 2016 [Member] Schoemann Note [Member] Second Convertible Note [Member] Second Extension Agreement [Member] Second Note [Member] Second Quarter of 2017 [Member] Second Tranche [Member] Securities Purchase Agreement [Member] Senior Convertible Note [Member] Settlement Agreement [Member] Remaining Life (yrs), Ending. Shares issued for consulting services. Shares issued for debt conversion. Shares issued for financing costs. Shares issued for prepaids. Shares issued to officers, directors and consultants. Shares to be issued. Shares to be Issued [Member] Short Term Notes [Member] Six Tranches [Member] Stock issued during period shares for financing costs. Stock Issued During Period Shares For Prepaid Services. Shares issued to officers, directors and cosultants, shares. Vested preferred shares. Stockissued during period value for financing costs. Stock Issued During Period Value For Prepaid Services. Shares issued to officers, directors and cosultants. Stock Option Plan [Member] Stock Option Plan1 [Member] Stock Option Plan 2 [Member] 10% Convertible Promissory Note Fourteen [Member] Third and Fourth Tranches [Member] Third Party [Member] Third Party Provider [Member] Third Tranche [Member] Third Tranche [Member]. 3% Convertible Promissory Note [Member] 3% Fixed Convertible Promissory Note [Member] 3% Fixed Convertible Promissory Note [Member] 3% Fixed Convertible Promissory Note One [Member] 3% Convertible Promissory Note [Member] 3% Convertible Promissory Note [Member] 3% Fixed Convertible Promissory Note [Member] Three Tranches [Member] 12% Convertible Promissory Note Four [Member] 12% Convertible Promissory Note [Member] 12% Convertible Promissory Note Eight [Member] 12% Convertible Promissory Note Five [Member] 12% Convertible Promissory Note Nine [Member] 12% Convertible Promissory Note One [Member] 12% Convertible Promissory Note Two [Member] 12% Convertible Promissory Note Seven [Member] 12% Convertible Promissory Note Six [Member] 12% Convertible Promissory Note Three [Member] 12% Fixed Convertible Promissory Note [Member] 12% Fixed Convertible Promissory Note Four [Member] 12% Fixed Convertible Promissory Note [Member] 12% Fixed Convertible Promissory Note 1 [Member] 12% Fixed Convertible Promissory Note Three [Member] 12% Fixed Convertible Promissory Note 2 [Member] 12% Fixed Convertible Promissory Note One [Member] 12% Fixed Convertible Promissory Note Two [Member] 12% Convertible Promissory Note Eight [Member] 12% Convertible Promissory Note Eleven [Member]. 12% Convertible Promissory Note Five [Member] 12% Convertible Promissory Note Four [Member] 12% Convertible Promissory Note Nine [Member] 12% Convertible Promissory Note One [Member] 12% Convertible Promissory Note Seven [Member] 12% Convertible Promissory Note Six [Member] 12% Convertible Promissory Note Ten [Member] 12% Convertible Promissory Note Thirteen [Member] 12% Convertible Promissory Note Three [Member] 12% Convertible Promissory Note Twelve [Member]. 12% Convertible Promissory Note Two [Member] 12% Fixed Convertible Promissory Note Five [Member] 12% Fixed Convertible Promissory Note One [Member] 12% Fixed Convertible Promissory Note Three [Member] 12% Fixed Convertible Promissory Note Two [Member] 20 Months Prior to February 2017 [Member] Two Back-End Notes [Member]. Two Convertible Notes [Member] 2018 Equity Incentive Plan [Member] 2015 Stock Option Plan [Member] United States Federal District Count [Member] Warrant 1 [Member] Warrants [Member] Wellness Industry [Member]. Working capital. Stock issued during period value reverse stock splits. Newly authorized redeemable preferred stock percentage. Monthly [Member] 12- month Advisory Services Agreement [Member] April 2018 for Twelve Months [Member] Shares issued during period commitment fee, shares. Shares issued during period commitment fee. Diligence fee. Number of Warrants, exercisable, Ending balance. Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share. Weighted Average Exercise Price, Exercisable Ending. Share Based Compensation Arrangement By Share Based Payment Award Non Option Grand In Period Weighted Average Exercise Price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price. Remaining Life (yrs), Beginning. Remaining Life (yrs), Exercisable Ending. Remaining Life (yrs), Ending. Intrinsic Value, Warrants Granted. Intrinsic Value, Warrants Exercised. Intrinsic Value, Warrants Cancelled. Intrinsic Value, Warrants Outstanding Balance. Intrinsic Value, Warrants Exercisable, Ending Balance. original issue discount. Capital Call [Member] Former CEO [Member] Arrears in fees amount. Services Agreement [Member] Agreement description. Bistromatics Inc. [Member] Number of vested preferred shares. Percentage of rights in appointment of officers. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Other Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Shares, Outstanding 10. Stock Options and Warrants ContributedServices SharesIssuedForFinancingCosts Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable, Related Parties Significant Accounting Policies [Table] Increase (Decrease) in Employee Related Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Debt Payments of Debt Issuance Costs Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations SharesIssuedForDebtConversion Interest Payable, Current Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisableWeightedAverageNumberOfShare ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsicValue ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodExercisableGrantDateIntrinsicValue Derivative Liability [Default Label] EX-101.PRE 13 ewll-20200630_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2020
Aug. 07, 2020
Cover [Abstract]    
Entity Registrant Name eWELLNESS HEALTHCARE Corp  
Entity Central Index Key 0001550020  
Document Type 10-Q  
Document Period End Date Jun. 30, 2020  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business Flag true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   87,324,044,69.
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2020  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Condensed Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
CURRENT ASSETS    
Cash $ 4,075 $ 240,722
Accounts Receivable 129,872 3,635
Prepaid expenses 21,763 157,139
Total current assets 155,710 401,496
Property & equipment, net 16,268 22,810
Intangible assets, net 8,000 9,000
TOTAL ASSETS 179,978 433,306
CURRENT LIABILITIES    
Accounts payable and accrued expenses 733,025 314,287
Accounts payable - related party 782,832 582,832
Accrued expenses - related party 121,107 138,868
Accrued compensation 357,965 532,974
Convertible debt, net of discount 1,977,769 2,240,408
Derivative liability 4,297,437 3,529,974
Total current liabilities 8,270,135 7,339,343
Total Liabilities 8,270,135 7,339,343
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT    
Preferred stock, authorized 20,000,000 shares, $.001 par value, 476,667 and 250,000 shares issued and outstanding, respectively 477 250
Common stock, authorized 20,000,000,000 shares, $.001 par value, 7,851,724,496 and 12,752,084 issued and outstanding, respectively 7,851,725 12,752
Shares to be issued 76 150
Additional paid in capital 21,409,110 23,942,830
Accumulated deficit (37,351,545) (30,862,019)
Total Stockholders' Deficit (8,090,157) (6,906,037)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 179,978 $ 433,306
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 476,667 250,000
Preferred stock, shares outstanding 476,667 250,000
Common stock, shares authorized 20,000,000,000 20,000,000,000
Common stock, par value $ .001 $ .001
Common stock, shares issued 7,851,724,496 12,752,084
Common stock, shares outstanding 7,851,724,496 12,752,084
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Income Statement [Abstract]        
REVENUE $ 123,780 $ 138,155
OPERATING EXPENSES        
Executive compensation 187,000 102,000 374,000 204,000
General and administrative 88,553 324,858 435,243 575,352
Professional fees 383,163 534,980 850,581 1,249,141
Total Operating Expenses 658,716 961,838 1,659,824 2,028,493
Loss from Operations (534,936) (961,838) (1,521,669) (2,028,493)
OTHER INCOME (EXPENSE)        
Interest income 6 1 17
Gain (loss) on derivative liability (2,217,052) (61,431) (4,199,959) 617,967
Loss on disposal of asset (3,866) (3,866)
Interest expense (205,073) (742,047) (764,033) (1,693,272)
Net Loss before Income Taxes (2,960,927) (1,765,310) (6,489,526) (3,103,781)
Income tax expense
Net Loss $ (2,960,927) $ (1,765,310) $ (6,489,526) $ (3,103,781)
Basic and diluted (loss) per share $ (0.00) $ (0.01) $ (0.00) $ (0.01)
Weighted average shares outstanding 5,181,476,648 219,592,981 2,672,747,473 215,560,585
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Reconciliation of Stockholders' Deficit (Unaudited) - USD ($)
Preferred Shares [Member]
Common Stock [Member]
Shares to be Issued [Member]
Additional Paid in Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2018 $ 4,128 $ 17,416,117 $ (21,401,234) $ (3,980,989)
Balance, shares at Dec. 31, 2018 4,128,139        
Contributed services 108,000 108,000
Shares issued for debt conversion $ 125 401,117 401,242
Shares issued for debt conversion, shares 125,574        
Shares issued for cash $ 16 59,084 59,100
Shares issued for cash, shares 16,000        
Shares issued for financing costs $ 20   114,980   115,000
Shares issued for financing costs, shares 20,000        
Shares issued for prepaid services $ 80 458,670   458,750
Shares issued for prepaid services, shares 80,217        
Shares issued for services $ 60 339,573 339,633
Shares issued for services, shares 59,500        
Derivative liability 563,327 563,327
Net loss (3,103,781) (3,103,781)
Balance at Jun. 30, 2019 $ 4,429 19,460,868 (24,505,015) (5,039,718)
Balance, shares at Jun. 30, 2019 4,429,430        
Balance at Dec. 31, 2018 $ 4,128 17,416,117 (21,401,234) (3,980,989)
Balance, shares at Dec. 31, 2018 4,128,139        
Balance at Dec. 31, 2019 $ 250 $ 12,752 150 23,942,830 (30,862,019) (6,906,037)
Balance, shares at Dec. 31, 2019 250,000 12,752,084        
Balance at Mar. 31, 2019 $ 4,346 19,012,024 (22,739,705) (3,723,334)
Balance, shares at Mar. 31, 2019 4,346,792        
Contributed services 54,000 54,000
Shares issued for debt conversion $ 24 53,732 53,756
Shares issued for debt conversion, shares 23,629        
Shares issued for cash $ 16 59,084 59,100
Shares issued for cash, shares 16,000        
Shares issued for prepaid services $ 10   52,990 53,000
Shares issued for prepaid services, shares 10,000        
Shares issued for services $ 33 158,051 158,084
Shares issued for services, shares 33,009        
Derivative liability 70,987 70,987
Net loss (1,765,310) (1,765,310)
Balance at Jun. 30, 2019 $ 4,429 19,460,868 (24,505,015) (5,039,718)
Balance, shares at Jun. 30, 2019 4,429,430        
Balance at Dec. 31, 2019 $ 250 $ 12,752 150 23,942,830 (30,862,019) (6,906,037)
Balance, shares at Dec. 31, 2019 250,000 12,752,084        
Contributed services 108,000 108,000
Shares issued for debt conversion $ 7,838,257 (6,681,896) 1,156,361
Shares issued for debt conversion, shares 7,838,256,204        
Shares issued for services $ 668 (74) 191 785
Shares issued for services, shares 668,332        
Derivative liability 3,360,260 3,360,260
Shares issued to officers, directors and consultants 227 $ 679,773 $ 680,000
Shares issued to officers, directors and consultants, shares $ 226,667        
Shares issued for rounding - 50:1 split 48 (48)
Shares issued for rounding - 50:1 split, shares 47,876        
Net loss         $ (6,489,526) $ (6,489,526)
Balance at Jun. 30, 2020 $ 477 $ 7,851,725 $ 76 $ 21,409,110 (37,351,545) (8,090,157)
Balance, shares at Jun. 30, 2020 476,667 7,851,724,496        
Balance at Mar. 31, 2020 $ 375 $ 1,430,006 26,285,825 (34,390,618) (6,674,412)
Balance, shares at Mar. 31, 2020 375,000 1,430,005,454        
Contributed services 54,000 54,000
Shares issued for debt conversion $ 6,421,466 (6,047,649) 373,817
Shares issued for debt conversion, shares 6,421,465,710        
Shares issued for services $ 253 76 (201) 128
Shares issued for services, shares 253,332        
Derivative liability 812,237 812,237
Shares issued to officers, directors and consultants 102 304,898 305,000
Shares issued to officers, directors and consultants, shares 101,667        
Net loss (2,960,927) (2,960,927)
Balance at Jun. 30, 2020 $ 477 $ 7,851,725 $ 76 $ 21,409,110 $ (37,351,545) $ (8,090,157)
Balance, shares at Jun. 30, 2020 476,667 7,851,724,496        
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical)
 6 Months Ended
Dec. 16, 2019
Jun. 30, 2020
Statement of Stockholders' Equity [Abstract]    
Reverse stock split, description 1:50 reverse split 50:1 split
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Condensed Statement of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Cash flows from operating activities    
Net loss $ (6,489,526) $ (3,103,781)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,676 2,840
Contributed services 108,000 108,000
Shares issued for officers, directors and consultants 344,960
Shares issued for consulting services 785 339,633
Shares issued for financing costs 93,433 115,000
Amortization of debt discount and prepaids 725,250 1,736,987
(Gain) loss on derivative liability 4,199,959 (617,967)
Loss on disposal of asset 3,866
Changes in operating assets and liabilities    
Prepaid expense (9,916) (37,628)
Accounts receivable (126,237)
Accounts payable and accrued expenses 513,643 83,297
Accounts payable - related party 196,460 (9,981)
Accrued expenses - related party 31,509 (13,560)
Accrued compensation 122,491 (43,279)
Net cash used in operating activities (281,647) (1,440,439)
Cash flows from investing activities    
Purchase of equipment (541)
Net cash used in investing activities (541)
Cash flows from financing activities    
Proceeds from issuance of common stock 59,100
Issuance of convertible debt 52,800 1,968,900
Payments on debt (639,550)
Debt issuance costs (7,800) (248,150)
Net cash provided by financing activities 45,000 1,140,300
Net increase (decrease) in cash (236,647) (300,680)
Cash, beginning of period 240,722 383,335
Cash, end of period 4,075 82,655
Cash paid for:    
Taxes 1,856
Interest Expense 275,814
Non cash items:    
Derivative liability and debt discount issued with new notes 1,769,048
Shares issued for debt conversion 1,156,360 401,242
Shares issued for prepaids $ 458,750
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.20.2
The Company
 6 Months Ended
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company

Note 1. The Company

 

The Company and Nature of Business

 

eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated minimal revenues to date.

 

eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. Our business model is to have large-scale employers use our PHZIO platform as a fully PT monitored corporate musculoskeletal treatment (“MSK”) wellness program. The Company’s PHZIO home physical therapy assessment and exercise platform has been designed to disrupt the $30 billion physical therapy market, the $4 billion MSK market and the $8 billion corporate wellness industry. PHZIO re-defines the way MSK physical therapy can be delivered. PHZIO is the first real-time remote monitored 1-to-many MSK physical therapy platforms for home use.

 

On May 22, 2020, the Company received and accepted the resignations of Brandon Rowberry and Rochelle Pleskow as independent directors. Their letters of resignation state the reason for their resignations were to permit them to pursue other business opportunities and further stated that they have had no disagreements with the operations, policies or practices of the Company. Also, on May 22, 2020, the Company received a letter of resignation from Darwin Fogt resigning as CEO, President and director of the Company and a separate letter of resignation from Curtis Hollister, resigning as CTO and director of the Company. Messrs. Fogt and Hollister are executive officers and principals of Bistromatics Inc., organized under the laws of Canada (“Bistromatics”).

 

On November 12, 2016, the Company entered into a Services Agreement with Bistromatics (the “Bistromatics Agreement”) pursuant to which Bistromatics agreed to provide operational services to the Company for its PHZIO System including development, content editing and training, support and maintenance, billing, hosting and oversight, among other services. Reference is made to the Company’s Form 8-K filed on November 21, 2016, which Form 8-K was signed by Darwin Fogt as CEO on behalf of the Company, regarding the disclosure of the Bistromatics Agreement. The Services Agreement included a provision granting Bistromatics the right to appoint 40% of the Registrant’s Board of Directors, resulting in the appointment of Messrs. Fogt and Hollister as members of the Company’s Board. Although both Companies continue to abide by the Services Agreement the Company is in arrears in fees to Bistromatics for approximately $750,000 as of March 31, 2020. The Service Agreement expired during the 1st quarter of 2020 and the parties continue to discuss the formation of a new Services Agreement.

 

Pursuant to communications between the Company and Darwin Fogt and Curtis Hollister regarding their resignations as executive officers and directors of the Company, which resignations were accepted by the Company’s Board on June 1, 2020, Messrs. Fogt and Hollister represented to the Company that Bistromatics and its management will continue to provide support services to the Company’s PHZIO System, In addition, both Darwin Fogt and Curtis Hollister confirmed that they have had no disagreements with the operations, policies or practices of the Company.

 

In connection with the resignation of Darwin Fogt as CEO, the Registrant’s Board of Directors has appointed Douglas MacLellan, who has served as the Company’s Chairman since May 2013, as Chief Executive Officer in addition to continuing to serve as the Chairman of the Board of Directors.

 

As noted above, the Companies PHZIO and MSK360 systems are currently operated on behalf of the Company by Bistromatics Inc. in Canada. These services are still operational and continues to treat EWLL’s corporate patients and customers.

 

We are in the process of completing a new Services Agreement with Bistromatics, that, when completed, will likely re-position EWLL as a Value Added Reseller (“VAR”) of the PHZIO & MSK360 platforms and allow EWLL to earn marketing fees and would also be granted a significant percentage ownership of Bistromatics in return for  transferring the marketing and IP rights for the PHZIO and MSK360 platforms from EWLL to Bistromatics.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2020 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2020. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019.

 

The information regarding common stock shares, options and warrants throughout this document have been adjusted to reflect the 1:50 reverse split authorized by the Board of Directors on December 16, 2019 and further approved by FINRA on February 12, 2020.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 

Going Concern

 

For the six months ended June 30, 2020, the Company had revenues of $138,155. The Company has an accumulated loss of $37,351,545 and a working capital deficit of $8,114,425. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Fair Value of Financial Instruments

 

As of June 30, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative Liability   $ 4,297,437     $            -     $             -     $ 4,297,437  
Total Liabilities measured at fair value   $ 4,297,437     $ -     $ -     $ 4,297,437  

 

As of December 31, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative Liability   $ 3,529,974     $            -     $             -     $ 3,529,974  
Total Liabilities measured at fair value   $ 3,529,974     $ -     $ -     $ 3,529,974  
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions
 6 Months Ended
Jun. 30, 2020
Related Party Transactions [Abstract]  
Related Party Transactions

Note 3. Related Party Transactions

 

In November 2016, the Company signed an agreement with a programming company (“PC”) within which one of the Company’s former directors and Chief Technical Officer (“CTO”) is the Chief Marketing Officer. The agreement is for additional features to be programmed for the launch of the PHZIO platform. The Company is to pay a monthly base fee of $100,000 for the development and compensation for the Company’s CEO and CTO. Following payment of the initial $100,000, the Company is obligated to only pay $50,000 monthly until the PC has successfully signed and collected the first monthly service fee for 100 physical therapy clinics to use the PHZIO platform. The PC will also have the right to appoint 40% of the directors. At the periods ended June 30, 2020 and December 31, 2019, the Company had a payable of $782,832 and $582,832, respectively. The CTO resigned his officer and director position on June 1, 2020.

 

The Company signed an agreement with the former CEO for administrative physical therapy consulting. The agreement provides that the former CEO will provide non-clinical administrative services in the various states where the Phzio companies are located. The Company is to pay the former CEO the sum of $3,500 per month. Since the former CEO resigned his officer and director position on June 1, 2020, any amounts owed to him are included in accounts payable.

 

Throughout the six months ended June 30, 2020, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of June 30, 2020 and December 31, 2019 were $0 and $1,368, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $121,107 and $137,500 as of June 30, 2020 and December 31, 2019, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $357,965 and $532,974 as of June 30, 2020 and December 31, 2019, respectively.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Notes Payable
 6 Months Ended
Jun. 30, 2020
Debt Disclosure [Abstract]  
Convertible Notes Payable

Note 4. Convertible Notes Payable

 

Six Months Ended June 30, 2020

 

In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. During the six months ended June 30, 2020, the Company accrued interest expense of $1,719.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Equity Transactions
 6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Equity Transactions

Note 5. Equity Transactions

 

Preferred Stock

 

The total number of shares of preferred stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $0.001 per share. During the year ended December 31, 2019, the Company authorized the issuance of 1,000,000 shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $3,000,000 and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two directors resigned and on June 1, 2020, three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. During the six months ended June 30, 2020, there were 226,667 preferred shares that vested and $297,500 was recorded to reduce accrued compensation; $37,250 was recorded to reduce accrued directors’ fees, and $345,250 was recorded as expense for a total of $680,000. As of June 30, 2020, there were 476,667 vested preferred shares for a total value of $1,430,000.

 

In April 2020, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series D Preferred Stock in which the Board authorized a new series of Preferred Stock to be designated as Series D. The Board authorized two hundred thousand (200,000) shares to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock.

 

The Series D Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation other than the Corporation’s newly authorized 13% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred”); (ii) on parity with all equity securities issued by the Corporation with terms specifically providing that the Series B Preferred ranks on parity, except with respect to voting rights on which the Series B Preferred ranks junior to the Series D Preferred and except with respect to rights to the payment of dividends and the distribution of assets upon any liquidation, dissolution or winding up of the Corporation, which the Series B Preferred ranks senior to the Series D Preferred; and (iii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others in) existing subsidiaries of the Corporation. The term “equity securities” shall not include convertible debt securities The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time.

 

Common Stock

 

On February 12, 2020, FINRA approved a 1:50 reverse split of the Company’s common stock. As noted throughout this document, all common shares are stated as if the 1:50 reverse split had been completed as of the beginning of the year ended December 31, 2019. Following the approval, the Company’s stock began trading under the symbol “EWLLD”. Due to rounding issues for the reverse split, the Company issued 47,876 additional shares of common stock.

 

On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (1,900,000,000) shares of Common Stock to twenty billion (20,000,000,000) shares of Common Stock. On February 19, 2019, the Company filed Articles of Amendment to the Company’s Articles of Incorporation to implement the Authorized Common Stock Share Increase with the State of Nevada.

 

Six Months Ended June 30, 2020

 

In January 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 shares of common stock monthly. The Company issued 80,000 shares of common stock with a value of $126. The Company needs to issue an additional 40,000 shares of common stock with a value of $8. In addition, the Company is to also pay the advisor a monthly fee of $2,500.

 

During the six months ended June 30, 2020, the Company issued a total of 7,838,256,204 shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $959,835 of principal, $103,093 of accrued interest and $93,433 of financing costs.

 

During the six months ended June 30, 2020, the Company issued 588,332 shares of common stock for consultant services valued at $1,597.

 

Six Months Ended June 30, 2019

 

On February 7, 2019, the Company executed an amendment to a contract executed on April 8, 2018 for twelve months for consulting services. The Company issued 5,000 shares of common stock at the signing of the contract valued at $30,500 that is being amortized over the life of the contract.

 

On March 22, 2019, the Company issued 65,217 shares of common stock to an institutional investor as part of a promissory note. These shares are returnable if the Company repays the promissory note before the maturity date. The value of these shares is $375,000 which was recorded as prepaid until the six-month maturity has passed. The Company also issued 20,000 shares of common stock to the institutional investor as a commitment fee. The value of these shares is $115,000.

 

On April 2, 2019, the Company issued 16,000 shares of common stock pursuant to a capital call notice in relation to an Equity Purchase Agreement dated June 18, 2018. The capital call totaled $59,100.

 

On May 17, 2019, the Company executed a contract for three months for consulting services. The Company issued 10,000 shares of common stock at the signing of the contract valued at $53,000 that is being amortized over the life of the contract. At the end of the three months, the Company is to issue another 10,000 shares of common stock.

 

During the six months ended June 30, 2019, the Company issued 59,500 shares of common stock to consultants for services rendered in accordance to consulting agreements. The value of these shares is $339,633.

 

During the six months ended June 30, 2019, the Company issued 125,574 shares of common stock for debt conversion totaling $401,242 which includes $380,250 principal, $18,992 accrued interest and $2,000 due diligence fee.

 

Stock Options

 

The following is a summary of the status of all Company’s stock options as of June 30, 2020 and changes during the six months ended on that date:

 

          Weighted              
    Number
of Stock		     Average
Exercise		     Remaining     Intrinsic  
    Options     Price     Life (yrs)     Value  
Outstanding at December 31, 2019     57,000     $ 40.00       1.1     $               -  
Granted     -       -                  
Exercised     -       -                  
Cancelled     -       -                  
Outstanding at June 30, 2020     57,000       40.00       .6     $ -  
Options exercisable at June 30, 2020     57,000     $ 40.00       .6     $ -  

 

Warrants

 

The following is a summary of the status of the Company’s warrants as of June 30, 2020 and changes during the six months ended on that date:

 

          Weighted              
    Number of     Average
Exercise		     Remaining     Intrinsic  
    Warrants     Price     Life (yrs.)     Value  
Outstanding at December 31, 2019     42,015     $ 11.94       1.9     $              -  
Granted     -       -       -       -  
Exercised     -       -       -       -  
Cancelled     (10,000 )     17.50       -       -  
Outstanding at June 30, 2020     32,015     $ 10.20       1.0     $ -  
Warrants exercisable at June 30, 2020     32,015     $ 10.20       1.0     $ -  
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments, Contingencies
 6 Months Ended
Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingencies

Note 6. Commitments, Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Valuation
 6 Months Ended
Jun. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Valuation

Note 7. Derivative Valuation

 

The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.

 

The debt discount is amortized over the life of the note and recognized as interest expense. For the six months ended June 30, 2020 and 2019, the Company amortized the debt discount of $594,705 and $1,401,501, respectively.

 

During the six months ended June 30, 2020, the Company had the following activity in the derivative liability account:

 

    Notes  
Derivative liability at December 31, 2019   $ 3,529,974  
Addition of new conversion option derivatives     -  
Conversion of note derivatives     (3,432,496 )
Change in fair value     4,199,959  
Derivative liability at June 30, 2020   $ 4,297,437  

 

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

Stock price at valuation date   $ .0002  
Exercise price of warrants   $ 12.50  
Conversion rate of convertible debt   $ .00007-.00014  
Risk free interest rate     .10%-.27 %
Stock volatility factor     347.96-1322.92 %
Years to Maturity     .02 – .55  
Expected dividend yield     None  
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events
 6 Months Ended
Jun. 30, 2020
Subsequent Events [Abstract]  
Subsequent Events

Note 8. Subsequent Events

 

From July 1 until the filing of this report, the Company issued 880,679,972 shares of common stock for convertible debt conversion totaling $54,322 which includes $50,362 principal and $3,960 accrued interest
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2020 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2020. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019.

 

The information regarding common stock shares, options and warrants throughout this document have been adjusted to reflect the 1:50 reverse split authorized by the Board of Directors on December 16, 2019 and further approved by FINRA on February 12, 2020.
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.
Going Concern

Going Concern

 

For the six months ended June 30, 2020, the Company had revenues of $138,155. The Company has an accumulated loss of $37,351,545 and a working capital deficit of $8,114,425. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

As of June 30, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative Liability   $ 4,297,437     $            -     $             -     $ 4,297,437  
Total Liabilities measured at fair value   $ 4,297,437     $ -     $ -     $ 4,297,437  

 

As of December 31, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative Liability   $ 3,529,974     $            -     $             -     $ 3,529,974  
Total Liabilities measured at fair value   $ 3,529,974     $ -     $ -     $ 3,529,974  
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Summary of Assets and Liabilities Fair Value on Recurring Basis

As of June 30, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative Liability   $ 4,297,437     $            -     $             -     $ 4,297,437  
Total Liabilities measured at fair value   $ 4,297,437     $ -     $ -     $ 4,297,437  

 

As of December 31, 2019, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

    Total     Level 1     Level 2     Level 3  
Derivative Liability   $ 3,529,974     $            -     $             -     $ 3,529,974  
Total Liabilities measured at fair value   $ 3,529,974     $ -     $ -     $ 3,529,974  
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Equity Transactions (Tables)
 6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Summary of Stock Options Activity

The following is a summary of the status of all Company’s stock options as of June 30, 2020 and changes during the six months ended on that date:

 

          Weighted              
    Number
of Stock		     Average
Exercise		     Remaining     Intrinsic  
    Options     Price     Life (yrs)     Value  
Outstanding at December 31, 2019     57,000     $ 40.00       1.1     $               -  
Granted     -       -                  
Exercised     -       -                  
Cancelled     -       -                  
Outstanding at June 30, 2020     57,000       40.00       .6     $ -  
Options exercisable at June 30, 2020     57,000     $ 40.00       .6     $ -  
Summary of Warrants Activity

The following is a summary of the status of the Company’s warrants as of June 30, 2020 and changes during the six months ended on that date:

 

          Weighted              
    Number of     Average
Exercise		     Remaining     Intrinsic  
    Warrants     Price     Life (yrs.)     Value  
Outstanding at December 31, 2019     42,015     $ 11.94       1.9     $              -  
Granted     -       -       -       -  
Exercised     -       -       -       -  
Cancelled     (10,000 )     17.50       -       -  
Outstanding at June 30, 2020     32,015     $ 10.20       1.0     $ -  
Warrants exercisable at June 30, 2020     32,015     $ 10.20       1.0     $ -  
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Valuation (Tables)
 6 Months Ended
Jun. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Liability

During the six months ended June 30, 2020, the Company had the following activity in the derivative liability account:

 

    Notes  
Derivative liability at December 31, 2019   $ 3,529,974  
Addition of new conversion option derivatives     -  
Conversion of note derivatives     (3,432,496 )
Change in fair value     4,199,959  
Derivative liability at June 30, 2020   $ 4,297,437
Schedule of Assumptions Used Black Scholes Valuation of Derivative

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

Stock price at valuation date   $ .0002  
Exercise price of warrants   $ 12.50  
Conversion rate of convertible debt   $ .00007-.00014  
Risk free interest rate     .10%-.27 %
Stock volatility factor     347.96-1322.92 %
Years to Maturity     .02 – .55  
Expected dividend yield     None
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.20.2
The Company (Details Narrative) - USD ($)
 6 Months Ended
Nov. 12, 2016
Jun. 30, 2020
Mar. 31, 2020
Physical therapy investment, description   PHZIO is the first real-time remote monitored 1-to-many MSK physical therapy platforms for home use.  
Physical Therapy Market [Member]      
Physical therapy assessment and exercise platform   $ 30,000,000,000  
MSK [Member]      
Physical therapy assessment and exercise platform   4,000,000,000  
Wellness Industry [Member]      
Physical therapy assessment and exercise platform   $ 8,000,000,000  
Bistromatics Inc. [Member] | Services Agreement [Member]      
Agreement description Bistromatics agreed to provide operational services to the Company for its PHZIO System including development, content editing and training, support and maintenance, billing, hosting and oversight, among other services. Reference is made to the Company's Form 8-K filed on November 21, 2016, which Form 8-K was signed by Darwin Fogt as CEO on behalf of the Company, regarding the disclosure of the Bistromatics Agreement. The Services Agreement included a provision granting Bistromatics the right to appoint 40% of the Registrant's Board of Directors, resulting in the appointment of Messrs. Fogt and Hollister as members of the Company's Board.    
Percentage of rights in appointment of director 40.00%    
Arrears in fees amount     $ 750,000
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Dec. 16, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Accounting Policies [Abstract]            
Reverse stock split, description 1:50 reverse split     50:1 split    
Revenues   $ 123,780 $ 138,155  
Accumulated deficit   (37,351,545)   (37,351,545)   $ (30,862,019)
Working capital deficit   $ 8,114,425   $ 8,114,425    
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Derivative Liability $ 4,297,437 $ 3,529,974
Total Liabilities measured at fair value 4,297,437 3,529,974
Level 1 [Member]    
Derivative Liability
Total Liabilities measured at fair value
Level 2 [Member]    
Derivative Liability
Total Liabilities measured at fair value
Level 3 [Member]    
Derivative Liability 4,297,437 3,529,974
Total Liabilities measured at fair value $ 4,297,437 $ 3,529,974
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2016
Jun. 30, 2020
Dec. 31, 2019
Monthly base fee   $ 2,500  
Accrued directors' fees   121,107 $ 137,500
Accrued executive compensation   357,965 532,974
Former CEO [Member]      
Accrued directors' fees   3,500  
Officers and Directors [Member]      
Due to related party   0 1,368
Programming Company [Member]      
Monthly base fee $ 100,000    
Related party transaction, description of transaction The agreement is for additional features to be programmed for the launch of the PHZIO platform. The Company is to pay a monthly base fee of $100,000 for the development and compensation for the Company's CEO and CTO. Following payment of the initial $100,000, the Company is obligated to only pay $50,000 monthly until the PC has successfully signed and collected the first monthly service fee for 100 physical therapy clinics to use the PHZIO platform. The PC will also have the right to appoint 40% of the directors.    
Fee payable per month $ 50,000    
Percentage of rights in appointment of director 40.00%    
Due to related party   $ 782,832 $ 582,832
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Notes Payable (Details Narrative)
 1 Months Ended
Mar. 31, 2020
USD ($)
Integer
Jun. 30, 2020
USD ($)
Debt face amount   $ 380,250
Accrued interest   $ 1,719
12% Convertible Promissory Note [Member]    
Debt face amount $ 52,800  
Debt interest stated rate 12.00%  
Debt maturity date Jan. 15, 2021  
Original issue discount $ 4,800  
Transaction costs $ 3,000  
Convertible debt percentage 70.00%  
Number of trading days | Integer 10  
Convertible notes, description After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date.  
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Equity Transactions (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 12, 2020
Dec. 16, 2019
May 17, 2019
Apr. 02, 2019
Mar. 22, 2019
Feb. 07, 2019
Apr. 30, 2020
Jan. 31, 2020
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Feb. 14, 2020
Preferred stock, shares authorized                 20,000,000   20,000,000   20,000,000  
Preferred stock, par value                 $ 0.001   $ 0.001   $ 0.001  
Deferred compensation                 $ 3,000,000   $ 3,000,000      
Preferred stock, value                 $ 477   $ 477   $ 250  
Common stock, par value             $ 0.001   $ .001   $ .001   $ .001  
Reverse stock split, description   1:50 reverse split                 50:1 split      
Common stock, shares authorized                 20,000,000,000   20,000,000,000   20,000,000,000  
Stock issued during the period, value                   $ 59,100   $ 59,100    
Monthly base fee                 $ 2,500   $ 2,500      
Principal amount                 380,250   380,250      
Accrued interest                 18,992   18,992      
Shares issued during period for services, value                 128 158,084 785 339,633    
Debt conversion of common stock value                 373,817 $ 53,756 1,156,361 $ 401,242    
Diligence fee                 2,000   $ 2,000      
Convertible Notes One [Member]                            
Shares issued for debt conversion, shares                     7,838,256,204      
Principal amount                 959,835   $ 959,835      
Accrued interest                 $ 103,093   103,093      
Financing costs                     $ 93,433      
12- month Advisory Services Agreement [Member]                            
Stock issued during the period               80,000     40,000      
Stock issued during the period, value               $ 126     $ 8      
Monthly base fee               $ 2,500            
12- month Advisory Services Agreement [Member] | Monthly [Member]                            
Stock issued during the period               20,000            
Equity Purchase Agreement [Member] | Capital Call [Member]                            
Stock issued during the period       16,000                    
Stock issued during the period, value       $ 59,100                    
Series D Preferred Stock [Membe                            
Newly authorized redeemable preferred stock percentage             13.00%              
Preferred stock voting rights             The term "equity securities" shall not include convertible debt securities The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time.              
Preferred Shares [Member]                            
Conversion of stock, shares                     40      
Conversion of stock, description                     The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance.      
Vested preferred shares                     226,667      
Stock option expense                     $ 297,500      
Accrued directors fees                     37,250      
Expenses                     345,250      
Total expenses                     $ 680,000      
Number of vested preferred shares                 476,667   476,667      
Preferred stock, value                 $ 1,430,000   $ 1,430,000      
Stock issued during the period                        
Stock issued during the period, value                        
Shares issued for debt conversion, shares                    
Shares issued during period for services, shares                    
Shares issued during period for services, value                    
Debt conversion of common stock value                    
Common Stock Two [Member]                            
Common stock, shares authorized                 20,000,000,000   20,000,000,000     1,900,000,000
Common Stock [Member]                            
Stock issued during the period                   16,000   16,000    
Stock issued during the period, value                   $ 16   $ 16    
Shares issued for debt conversion, shares                 6,421,465,710 23,629 7,838,256,204 125,574    
Shares issued during period for services, shares                 253,332 33,009 668,332 59,500    
Shares issued during period for services, value                 $ 253 $ 33 $ 668 $ 60    
Debt conversion of common stock value                 $ 6,421,466 $ 24 $ 7,838,257 $ 125    
Officers, Directors and Consultants [Member]                            
Preferred stock, shares authorized                         1,000,000  
Board of Directors [Member] | Series D Preferred Stock [Membe                            
Preferred stock, shares authorized             200,000              
Board of Directors [Member] | Common Stock One [Member]                            
Reverse stock split, description 1:50 reverse split                       1:50 reverse split  
Stock issued during the period                         47,876  
Consultant [Member]                            
Shares issued during period for services, shares                     588,332      
Shares issued during period for services, value                     $ 1,597      
Consultant [Member] | Consulting Agreement [Member]                            
Shares issued during period for services, shares                       59,500    
Shares issued during period for services, value                       $ 339,633    
Consulting Services [Member]                            
Shares issued during period for services, shares     10,000             10,000        
Shares issued during period for services, value     $ 53,000                      
Consulting Services [Member] | April 2018 for Twelve Months [Member]                            
Shares issued during period for services, shares           5,000                
Shares issued during period for services, value           $ 30,500                
Investor [Member]                            
Shares issued for debt conversion, shares         65,217                  
Debt conversion of common stock value         $ 375,000                  
Shares issued during period commitment fee, shares         20,000                  
Shares issued during period commitment fee         $ 115,000                  
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Equity Transactions - Summary of Stock Options Activity (Details)
 6 Months Ended
Jun. 30, 2020
USD ($)
$ / shares
shares
Equity [Abstract]  
Number of Stock Options Outstanding, Beginning Balance | shares 57,000
Number of Stock Options Outstanding, Granted | shares
Number of Stock Options Outstanding, Exercised | shares
Number of Stock Options Outstanding, Cancelled | shares
Number of Stock Options Outstanding, Ending Balance | shares 57,000
Number of Stock Options exercisable, Ending Balance | shares 57,000
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares $ 40.00
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares 40.00
Weighted Average Exercise Price Options exercisable, Ending Balance | $ / shares $ 40.00
Remaining Life (yrs) Outstanding, Beginning Balance 1 year 1 month 6 days
Remaining Life (yrs) Outstanding, Ending Balance 7 months 6 days
Remaining Life (yrs) Options exercisable, Ending Balance 7 months 6 days
Intrinsic Value Outstanding, Beginning Balance | $
Intrinsic Value Outstanding, Ending Balance | $
Intrinsic Value Options exercisable, Ending Balance | $
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Equity Transactions - Summary of Warrants Activity (Details)
 6 Months Ended
Jun. 30, 2020
USD ($)
$ / shares
shares
Equity [Abstract]  
Number of Warrants, Outstanding, Beginning Balance | shares 42,015
Number of Warrants, Granted | shares
Number of Warrants, Exercised | shares
Number of Warrants, Cancelled | shares (10,000)
Number of Warrants, Outstanding, Ending Balance | shares 32,015
Number of Warrants, exercisable, Ending balance | shares 32,015
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance | $ / shares $ 11.94
Weighted Average Exercise Price, Warrants Granted | $ / shares
Weighted Average Exercise Price, Warrants Exercised | $ / shares
Weighted Average Exercise Price, Warrants Cancelled | $ / shares 17.50
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance | $ / shares 10.20
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares $ 10.20
Remaining Life (yrs.) Warrants Outstanding, Beginning Balance 1 year 10 months 25 days
Remaining Life (yrs.) Warrants Outstanding, Ending Balance 1 year
Remaining Life (yrs.) Warrants Exercisable, Ending Balance 1 year
Intrinsic Value, Warrants Outstanding, Beginning Balance | $
Intrinsic Value, Warrants Granted | $
Intrinsic Value, Warrants Exercised | $
Intrinsic Value, Warrants Cancelled | $
Intrinsic Value, Warrants Outstanding, Ending Balance | $
Intrinsic Value, Warrants Exercisable, Ending Balance | $
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Valuation (Details Narrative) - USD ($)
 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Amortized of debt discount $ 725,250 $ 1,736,987
Derivative Liability [Member]    
Amortized of debt discount $ 594,705 $ 1,401,501
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Valuation - Schedule of Derivative Liability (Details) - Notes [Member]
 6 Months Ended
Jun. 30, 2020
USD ($)
Derivative liability, beginning balance $ 3,529,974
Addition of new conversion option derivatives
Conversion of note derivatives 4,199,959
Change in fair value 4,199,959
Derivative liability, ending balance $ 4,297,437
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) - Derivative Liability [Member]
 6 Months Ended
Jun. 30, 2020
$ / shares
Stock price at valuation date $ 0.0002
Exercise price of warrants $ 12.50
Valuation Technique, Option Pricing Model [Member] | Expected Dividend Yield [Member]  
Derivative liability, fair value measurement input percentage 0.00
Minimum [Member]  
Conversion rate of convertible debt $ 0.00007
Minimum [Member] | Valuation Technique, Option Pricing Model [Member] | Risk Free Interest Rate [Member]  
Derivative liability, fair value measurement input percentage 0.10
Minimum [Member] | Valuation Technique, Option Pricing Model [Member] | Stock Volatility Factor [Member]  
Derivative liability, fair value measurement input percentage 347.96
Minimum [Member] | Valuation Technique, Option Pricing Model [Member] | Years to Maturity [Member]  
Derivative liability, term 7 days
Maximum [Member]  
Conversion rate of convertible debt $ 0.00014
Maximum [Member] | Valuation Technique, Option Pricing Model [Member] | Risk Free Interest Rate [Member]  
Derivative liability, fair value measurement input percentage 0.27
Maximum [Member] | Valuation Technique, Option Pricing Model [Member] | Stock Volatility Factor [Member]  
Derivative liability, fair value measurement input percentage 1,322.92
Maximum [Member] | Valuation Technique, Option Pricing Model [Member] | Years to Maturity [Member]  
Derivative liability, term 6 months 18 days
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 14, 2020
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Shares issued for debt conversion   $ 373,817 $ 53,756 $ 1,156,361 $ 401,242
Debt face amount   380,250   380,250  
Accrued interest   $ 1,719   $ 1,719  
Subsequent Event [Member]          
Shares issued for debt conversion, shares 880,679,972        
Shares issued for debt conversion $ 54,322        
Debt face amount 50,362        
Accrued interest $ 3,960        
EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 121 287 1 false 42 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://ewellnesshealth.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Condensed Balance Sheets (Unaudited) Sheet http://ewellnesshealth.com/role/CondensedBalanceSheets Consolidated Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Condensed Statements of Operations (Unaudited) Sheet http://ewellnesshealth.com/role/CondensedStatementsOfOperations Consolidated Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Reconciliation of Stockholders' Deficit (Unaudited) Sheet http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit Reconciliation of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical) Sheet http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficitParenthetical Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Condensed Statement of Cash Flows (Unaudited) Sheet http://ewellnesshealth.com/role/CondensedStatementOfCashFlows Consolidated Condensed Statement of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - The Company Sheet http://ewellnesshealth.com/role/Company The Company Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://ewellnesshealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Convertible Notes Payable Notes http://ewellnesshealth.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Equity Transactions Sheet http://ewellnesshealth.com/role/EquityTransactions Equity Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Commitments, Contingencies Sheet http://ewellnesshealth.com/role/CommitmentsContingencies Commitments, Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Derivative Valuation Sheet http://ewellnesshealth.com/role/DerivativeValuation Derivative Valuation Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://ewellnesshealth.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Equity Transactions (Tables) Sheet http://ewellnesshealth.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://ewellnesshealth.com/role/EquityTransactions 18 false false R19.htm 00000019 - Disclosure - Derivative Valuation (Tables) Sheet http://ewellnesshealth.com/role/DerivativeValuationTables Derivative Valuation (Tables) Tables http://ewellnesshealth.com/role/DerivativeValuation 19 false false R20.htm 00000020 - Disclosure - The Company (Details Narrative) Sheet http://ewellnesshealth.com/role/CompanyDetailsNarrative The Company (Details Narrative) Details http://ewellnesshealth.com/role/Company 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies-SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails Summary of Significant Accounting Policies - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) Details 22 false false R23.htm 00000023 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://ewellnesshealth.com/role/RelatedPartyTransactions 23 false false R24.htm 00000024 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://ewellnesshealth.com/role/ConvertibleNotesPayable 24 false false R25.htm 00000025 - Disclosure - Equity Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative Equity Transactions (Details Narrative) Details http://ewellnesshealth.com/role/EquityTransactionsTables 25 false false R26.htm 00000026 - Disclosure - Equity Transactions - Summary of Stock Options Activity (Details) Sheet http://ewellnesshealth.com/role/EquityTransactions-SummaryOfStockOptionsActivityDetails Equity Transactions - Summary of Stock Options Activity (Details) Details 26 false false R27.htm 00000027 - Disclosure - Equity Transactions - Summary of Warrants Activity (Details) Sheet http://ewellnesshealth.com/role/EquityTransactions-SummaryOfWarrantsActivityDetails Equity Transactions - Summary of Warrants Activity (Details) Details 27 false false R28.htm 00000028 - Disclosure - Derivative Valuation (Details Narrative) Sheet http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative Derivative Valuation (Details Narrative) Details http://ewellnesshealth.com/role/DerivativeValuationTables 28 false false R29.htm 00000029 - Disclosure - Derivative Valuation - Schedule of Derivative Liability (Details) Sheet http://ewellnesshealth.com/role/DerivativeValuation-ScheduleOfDerivativeLiabilityDetails Derivative Valuation - Schedule of Derivative Liability (Details) Details 29 false false R30.htm 00000030 - Disclosure - Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Sheet http://ewellnesshealth.com/role/DerivativeValuation-ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails Derivative Valuation - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Details 30 false false R31.htm 00000031 - Disclosure - Subsequent Events (Details Narrative) Sheet http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://ewellnesshealth.com/role/SubsequentEvents 31 false false All Reports Book All Reports ewll-20200630.xml ewll-20200630.xsd ewll-20200630_cal.xml ewll-20200630_def.xml ewll-20200630_lab.xml ewll-20200630_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 50 0001493152-20-015226-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-20-015226-xbrl.zip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end